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I. INTRODUCTION 
In 1972, Janowsky and colleagues”” proposed that 
depression and mania are hyper- and hypo-choliner- 
gic states, respectively. The history of this article is il- 
luminating. It was cited only 4 times between 1972 
and 1975, but has now been referenced 207 times, 40 
in 1985. This growing interest attests to the useful- 
ness of the chohnergic hypothesis of depression as a 
construct. Researchers in’ both the basic and clinical 
sciences, including affective disorder experts, neuro- 
endocrinologists, polysomnologists, neurochemists 
and pharmacologists, have found it a unifying prin- 
ciple as well as a rich source of testable ideas. This ar- 
ticle reviews research directed by the cholinergic hy- 
pothesis. 
Various lines of research can be classified accord- 
ing to the strength of the evidence they provide for 
the cholinergic hypothesis. Behavioral or phenome- 
nological observations, neuroendocrine and poly- 
somnographic responses, and the supersensitivity of 
affective disorders probands to cholinergic challenge 
lend strong support. Moderately convincing evi- 
dence comes from the utility of antimuscarinics as an- 
tidepressants, from the capacity of centrally adminis- 
tered cholinomimetics and anticholinesterase to re- 
duce drive-reduction behavior and of systemically 
administered anticholinergic agents to increase oper- 
ant responding, and from the finding that tricychc 
withdrawal can produce atropine-sensitive signs and 
symptoms, among which is depressive symptomato- 
logy. Substances of abuse, including alcohol, canna- 
binoids, barbiturates, opiates, and antimuscarinic 
agents, either block the presynaptic release of acetyl- 
TABLE I 
choline or directly block postsynaptic muscarinic re- 
ceptors. Thus, substances of abuse - agents mod- 
ulating mood and affect or promoting hedonia - ap- 
pear to antagonize cholinergic systems. activate 
monoaminergic systems, or, as in the case of the stim- 
ulants, both, providing moderate or possible evi- 
dence for the cholinergic hypothesis and suggesting 
points of study. Preliminary studies on the effects of 
sleep deprivation, indicate alteration of cholinergic 
systems compatible with the cholinergic hypothesis. 
Studies on victims of suicide may also be of value, al- 
though conflicting reports on the density of muscarin- 
ic receptor binding sites in these subjects and meth- 
odological problems raise doubts with post-mortem 
studies. Table I lists various lines of evidence for the 
cholinergic hypothesis according to their strength. 
2. STRONG EVIDENCE FOR THE CHOLINERGIC HY- 
POTHESIS OF DEPRESSION 
Phenomenologic, polysomnographic, and neuro- 
endocrine studies, as well as experiments measuring 
the sensitivity of patients with depressive disorders to 
cholinergic challenge relative to psychiatric and nor- 
mal control subjects, provide relatively strong evi- 
dence for the hypothesis that depressive illness is as- 
sociated with cholinergic overdrive or a neurobiolog- 
ic characteristic that promotes its development. 
3. THE PHENO~ENOLOGICAL EVIDENCE 
Centrally active anticholinesterases and cholino- 
mimetics produce syndromes marked by dysphoria, 
psychomotor retardation, anergy, malaise, and a de- 
Evidence for a chotinergic mechanism in the pathophysioZogy of affective disorders 
Sources of evidence for the cholinergic hypothesis of depression classified according to strength of support which they accord. Some of 
these sources may eventually be of considerable support and currently have heuristic value because they promise to foster clinical and 
basic inquiry, Thus, current strength of support is a limited measure in the categorization of these 10 items. 
_ _ _~~_ .._~. _~~_ _.-.____ __~~_ ..__ ~. .__.. __ 
Strong Moderate Possible 
__~._.~_~ ._________ __..~___ ,._-_ ~~_ -__ .~ 
1. BehavioraliPhenomenological 5. Antimuscarinics have antidrepessant properties 9. Sleep deprivation data 
2. Neuroendocrine 6. Drive reduction studies 10. Postmortem studies 
3. Polysomnographic 7. Tricyclic, anticholinergic withdrawal phenomena 
4. Affective disorder probands are 
supersensitive to cholinergic agents 8. Drug abuse data 
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sire but inability to sleep 6,15,30,58,82,113,115,116,118,119, 
204,209. Grob et al.Po reported induction of depressive 
symptomatology by diisopropylflurophosphonate 
(DFP) nearly 40 years ago. Intramuscular adminis- 
tration of l-2 mg resulted in excessive dreaming, in- 
somnia, jitteriness, restlessness, increased tension, 
lability, subjective tremulousness, and confusion. 
Neostigmine did not cause these symptoms in 60 sub- 
jects. Rowntree et al.213 gave DFP to normal subjects 
for 7 days, 1 mg on Day 1 of the experiment and 2 mg 
on days 2-7. Depression, irritability, lassitude, apa- 
thy, decreased motor activity, tension, restlessness, 
emotional lability, and insomnia followed. Gershon 
and Shaws’ observed psychiatric sequelae of organo- 
phosphate poisoning in 16 subjects. Dysphoria, irri- 
tability, nightmares, extreme fatigue, memory and 
concentration impairment, and psychomotor retar- 
dation or agitation were common symptoms, all of 
which responded to atropine and cessation of expo- 
sure to the anticholinesterase. Bowers et al” gave or- 
ganophosphate EA-1701, being studied for military 
purposes, to 93 normal subjects. Thirty-seven exhi- 
bited a decline in whole blood cholinesterase activity 
to lo-40% of their baseline. Fifty-seven percent 
(57%) in this group experienced depressed mood, fa- 
tigue, weakness, slowed speech, and subjective mo- 
toric slowing. ‘Jitteriness’ and sleep disturbance were 
frequent. Sleep disturbance was marked by insomia 
and excessive, vivid, and frightening dreams. 
Physostigmine, a reversible anticholinesterase, 
produces depressive-like symptomatology~‘2~1~3~*i5- 
11g~204~205~209~227~266. Janowsky et al. ‘16 studied effects 
of this drug in 6 bipolar patients while they were man- 
ic. Placebo injections were followed by infusion of 
neostigmine or physostigmine. The latter was given 
in 0.25 mg or 0.5 mg doses every 5 min, until either 
behavioral change occurred or a total dose of 3.0 mg 
was reached. Response was monitored using a mod- 
ified version of the Beigel-Murphy Manic Rating” 
and the Bunney-Hamburg Scales23. The anticholi- 
nesterase induced significant decreases in the global 
manic intensity score and on the manic euphoria- 
grandiosity, ‘is talking’, ‘is active’, ‘jumps from one 
subject to another’, and ‘looks happy and cheerful’ 
subscales of the Beigel-Murphy scale”. The Bun- 
ney-Hamburg scale23 score more than doubled (indi- 
cating decreased manic symptoms and increaed de- 
pression). Patients were also rated on several O-5 
point scales, broadly measuring the dimension of be- 
havioral inhibition-activation. Scores increased on 
many of these scales, including (1) lethargy, (2) 
slowed thoughts, (3) ‘wants to say nothing’ (4) with- 
drawal, (5) apathy, (6) anergy, (7) ‘feels drained’, (8) 
hypoactivity, (9) ‘lacks thoughts’, (10) motoric retar- 
dation, (11) emotion~ly withdraw, and decreased 
on (12) cheerfulness, (13) friendliness, (14) ‘inter- 
acting’, (15) talkativeness. In summary, symptoms of 
mania diminished. 
El-Yousef et a1.58 studied effects of physostigmine 
on two chronic abusers of marijuana. This anticholi- 
nesterase counteracted the marijuana ‘high state’ 
and produced a profound depression in both. The de- 
pressive syndrome included feelings of uselessness, 
hopelessness, apathy, sadness, decreased thoughts 
and verbalizations, dysphoria, suicidal ideation, and 
extreme psychomotor retardation lasting 10 min in 
one subject and 30 min in the other. One subject’s 
distress was aborted by atropine sulfate 1 mg, i.v. 
Dilsaver et al.@ reported a similar syndrome which 
was marked by severe dysphoria, psychomotor retar- 
dation, suicidal thoughts, anorexia and anxiety fol- 
lowing discontinuation of thiothixene and benztro- 
pine in a chronic cannabis smoker. This syndrome 
also responded to high doses of atropine (1.2 mg, 
orally, every 4 hours). These uncontrolled observa- 
tions suggest the possibility that agents in marijuana 
supersensitize central cholinergic systems. 
Animal data also support this hypothesis. Rosen- 
blatt et a1.2” reported that treatment of rat with mari- 
juana potentiated the toxicity of physostigmine. Bio- 
chemical studies are corroborative and suggest a pos- 
sible mechanism. Kumbarachi and Nastok’53 found 
that d9-THC (tetrahydrocannabinol) caused a de- 
crease in the quanta1 release of acetylcholine at neu- 
romuscular junctions, and, with protracted applica- 
tion, complete blockade. Yoshimura et a12” ob- 
served increased in striatal and amygdaloid acetyl- 
choline content in response to treatment with d9- 
THC. This finding is consistent with a drug-induced 
increase in acetylcholine content due to diminished 
acetylcholine release. Layman and Miltonlm demon- 
strated that cannabinoids do in fact reduce acetylcho- 
line release at muscarinic junctions. Drugs signifi- 
cantly interfering with the quanta1 release of acetyl- 
choline are apt to denervate postsynaptic neurons 
pharmacologically, thereby producing up-regulation 
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and supersensitivity of cholinergic system. This phe- 
nomenon could account for the reactions observed by 
El Yousef et al.‘s and Dilsaver and colleagues’“. 
Janowsky et al.“s studied the effects of physostig- 
mine in 16 patients with affective and schizoaffective 
disorders and in 6 schizophrenics without affective 
symptoms under double blind conditions. Patients 
with an ‘affective component’ showed significant in- 
creases in depressed mood and a ‘generalized inhibi- 
tory state’ consisting of lethargy and emotional with- 
drawal after physostigmine infusion. Apathy, aner- 
gy, psychomotor retardation. fatigue, and decreases 
in thought production, social interaction, talkative- 
ness, and friendliness were also found. This cholino- 
lytic sensitive syndrome resembled the ‘psychomotor 
component of retarded depression’. 
Janowsky et al.115 observed that physostigmine 
and methylphenidate act antagonistically in both hu- 
mans”’ and animals. This finding is consistent with 
the hypothesis that depression and mania involve an 
imbalance of the cholinergic and adrenergic systems. 
Physostigmine also antagonized manic symptomato- 
logy in 12 bipolar and 24 schizophrenic patients when 
infused in 0.5 mg doses until either inhibition oc- 
curred or a total dose of 2.5 mg was reached’lh. Sev- 
eral O-5 point activation-inhibition scales, a modifi- 
cation of the Beigel-Murphy manic-state rating 
scale”, and independent global ratings for irritabili- 
Cholinergic-Monoaminergic Interaction Theory 
Monoaminergic Nuclei Activate RAS 
I+ 
Reticular Activating Systam (RAS) 
and Gigantocellular~Tegmental Field (FTG) 
Effects of Acatylcholine 
Are Locus Dependent - 
Locus Coeruleus i 
4 1 
Muscarinic Cholinerjc Outflow Produces 
Lc Cholinergic Limbic Nucki 
r+ 
Effects of Monoamines 
4 I 
mt on Specific 
Cholinergic Systems 
1. EEG activation khsynchrony~ 
2. Acrylchdina OuQut at Cortw 
3. Transition Non-REM to REM Sleep 
Fig. 1. This presents elements of the Cholinergic-Monoaminergic Interaction Theory. The reticular activating system (RAS) interacts 
with limbic aminergic nuclei involved in affecting behavioral arousal. Cholinergic pontine neurons (FIG) interact with adrenergic 
neurons of the locus coeruleus similarly in the regulation of REM-non-REM transitions. The RAS and FTG both produce cholinergic 
outflow and the output of acetylcholine at the cortex. This is essential to development of the electrocortical desynchrony which nor- 
mally accompanies behavioral arousal and the physiology of REM-non-REM shifts. Cholinergic limbic neurons interact with mono- 
aminergic cells to regulate and modulate mood, affect, neuroendocrine functions, psychomotor status and other variables relevant to 
affective and substance abuse disorders. These systems are auto- and inter-regulated. Thus, the value of monoaminergic variables is a 
function of the value of variables describing the cholinergic limbic nuclei and vice-versa. Please see text for further explanation. 
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ty, dysphoria, hostility, anger, wanting to be alone, 
crying, sadness, sleepiness, unusual thought content, 
conceptual disorganization, and blunted affect were 
employed. The antichohnesterase once again pro- 
duced ‘symptoms characteristic of psychomotor in- 
hibition‘ in both the schizophrenic and bipolar 
groups. Methylphenidate had opposite effects, which 
were either prevented or reversed by physostigmine. 
Carroll et aL3’ gave up to 4.2 mg of i.v. physostig- 
mine to two manic subjects and to another with corti- 
costeroid-induced psychosis with manic and confu- 
sional features. All were psychotic. The investigators 
concluded that physostigmine non-speci~cally affects 
psychomotor activity and produces anergia without 
altering manic thought disorder, i.e., the manic 
thought disorder has a mechanism distinct from the 
psychomotor disturbance characterizing mania, 
though the former may depend on the latter for ex- 
pression. 
Shopsin et al.‘*’ studied the effects of up to 6 mg of 
i.v. physostigmine in 3 manic patients using a double- 
blind design. Sedation, drowsiness, a desire but in- 
ability to sleep, confusion, difficulty concentrating, 
and reductions in spontaneous verbal production oc- 
curred. Provocation sometimes resulted in a full- 
blown display of manic ideation. The authors con- 
cluded that the delusional elements of manic psycho- 
pathology were not fundamentally altered. 
In contrast to Shopsin et al.**’ and Carroll et aL30, 
Davis and colleagues36 concfuded that physostigmine 
produced genuine depressive symptomatology and 
has antimanic properties, They catalogued the ef- 
fects of 4 mg of physostigmine given i.v. at a constant 
rate over 60 min to 8 manic subjects, using visual ana- 
logue and Pettersen’” mania scales to measure the 
intensity of symptoms. Six patients exhibited shifts 
from a manic state to one characteristic of significant 
depression. Visual analogue and Pettersenrg6 mania 
scales were used to measure the intensity of symp- 
toms. The possibility that anergia or nausea and vom- 
iting altered expression of clinical features integral to 
mania without modifying manic ideation was ex- 
plored. Subjects reported slowed thoughts, difficulty 
concentrating, and occasional dizziness after receiv- 
ing about 2 mg of physostigmine. Most experienced 
depressive cognition and dysphoria after receiving 3- 
4 mg of the drug, and a few even became tearful. On- 
set of nausea, vomiting, and anergia generally pre- 
ceded onset of dysphoria. 
Effects of physostigmine on mood in normal sub- 
jects is a topic of debate. Davis et a1.34,35 infused 3 mg 
of physostigmine or placebo into groups of 13 and 10 
normal subjects, respectively. A ‘physostigmiue syn- 
drome’ of decreased speech, slowed thoughts, mild 
sedation, expressionless faces, nausea, and de- 
creased spontaneous motor activity was evident after 
subjects received 152.0 mg, but placebo and 
physostigmine groups did not differ significantly. 
Two physostigmine but no placebo subjects, howev- 
er, became tearful and depressed. The investigators 
later learned one of the physostigmine-sensitive indi- 
viduals had a history of significant premenstrual de- 
pression and the other of marijuana abuse. Oppen- 
heim et al.“’ studied the effects of a bolus i.v. injec- 
tion of 1.25-2 mg of physostigmine on mood in 5 nor- 
mal subjects, using the modification of the Bunney- 
Hamburg23 scale adopted by Janowsky et a1.115,116. 
These subjects developed psychomotor retardation, 
but it was uncertain whether they experienced ge- 
nuine dysphoria. Thus, although procedures used to 
identify and quantitate variables and the power of 
statistical tests used to analyze data may have been 
insufficient to identify differences between the 
physostigmine and placebo conditions in some stud- 
ies of normal subjects, the effects of physostigmine in 
normals, if they exist, are subtle. 
How normal subjects respond to pharmacological- 
ly induced central cholinergic overdrive, however, is 
not necessarily germane to the question of whether 
central cholinergic overdrive plays a role in the gene- 
sis of affective disorders. Moreover, subjects devel- 
oping depressed mood in response to centrally acting 
chohnergic agents may possess pre-existing aberra- 
tions at central cholinergic loci resembling those of 
affective disorder patients and chronic abusers of 
marijuana; i.e., these aberrations may not be specific 
to affective disease. Such disturbances may permissi- 
vely promote development of affective disorders; al- 
ternatively, they could be a factor or one of a group 
of factors necessary but not sufficient to produce af- 
fective illness. It would therefore seem wise to screen 
subjects not only for personal affective pathology but 
also for illness in first-degree relatives, on the suppo- 
sition that such defects have a hereditary component. 
The effect of cholinergic challenge in normal vs af- 
fectively ill subjects using an ABA design (with sub- 
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jects as their own controls) may provide additional 
clues to the contribution of cholinergic overdrive to 
depressive symptomatology. Risch et al.‘“’ investi- 
gated the effects of physostigmine on mood and af- 
fect in 9 normal subjects screened for absence of per- 
sonal and family history of affective disorders and 
marijuana use. This study differed from those done 
previously in using self-reports of depressed mood to 
complement investigator completed ratings. Subjects 
received i.v. infusions of 0.022 mgikg of physostig- 
mine salicylate or saline in a randomized, double- 
blind, counterbalanced design. The anticholineste- 
rase-produced increases in depressive-like symptoms 
including decreased speech, sedation. lack of facial 
expression, reduced motor activity, dysphoria and 
depressive cognition. Self-reports of such symptoms 
began within 10 to 20 min of infusion and before the 
onset of nausea and vomiting. These investigators 
concluded that participants in earlier studies3”,3”,27’ 
may have developed depressed mood but failed to re- 
port it because of physostigmine-induced psychomo- 
tor retardation, withdrawal, and reduction in verbali- 
zation. Moreover, Davis et al.““.” rated subjects 
30-45 min after the physostigmine infusion, when 
most symptomatology may have resolved. In addi- 
tion, rater blindness was not addressed in the earlier 
reports35,3h. Finally. Risch et al.““’ used higher doses 
of physostigmine or a shorter infusion time than did 
previous investigators. 
Two studies suggest that affective disorder pa- 
tients show exaggerated mood changes, compared to 
psychiatric control subjects, in response to physostig- 
mine challenge. Janowsky et al.‘r’ studied 37 drug- 
free patients diagnosed by Research Diagnostic Cri- 
teria (RDC)‘s” to test the hypothesis that patients 
with depressive disorders are more sensitive to 
physostigmine than other psychiatric patients. Sub- 
jects were 17 affective disorder patients, 10 of whom 
had major depressive disorder and 7 mania, and a 
control group of 20 patients with ‘other’ psychiatric 
diagnoses (4 with schizoaffective disorder, 12 detoxi- 
fied alcoholics, two with histories of past drug abuse, 
and two with miscellaneous psychiatric disorders). 
Subjects received 0.022 mg/kg of physostigmine sali- 
cylate by i.v. infusion over 10 min on one day and pla- 
cebo on another. In comparison with the control 
group, affective disorder patients exhibited exagger- 
ated responses on the Brief Psychiatric Rating Scale 
( BPRS)‘3J depression subscale, investigator com- 
pleted ratings of activation, dysphoria, inhibition. 
subject completed ratings of inhibition, and the Pro- 
file of Mood States (POMS)” subscales of ten- 
sion-anxiety, depression-dejection, anger-hostili- 
ty, fatigue, and decrease in friendliness. Risch et 
al.‘“, using the same methodology on 14 affective dis- 
order subjects and 15 patients with ‘other’ diagnoses. 
confirmed the findings of Janowsky et al.““. 
In summary, anticholinesterases appear capable of 
producing depressive syndromes in susceptible, sub- 
jects. Physostigmine has been particularly useful in 
studying the role of cholinergic systems in the regula- 
tion of mood and affect. Cholinergic manipulations 
suggest that even normal subjects can experience 
dysphoria and other symptoms of melancholia with 
pharmacologic induction of central cholinergic over- 
drive. The strength of effect, however, is greater in 
affective disorder subjects. who appear to be super- 
sensitive to physostigmine challenge. 
4. NEUROENDOCRINE DATA 
Hypercortisolemia and unresponsiveness of the 
limbic-hypothalamic-pituitary-adrenal (LHPA) axis 
to feedback inhibition are confirmed features of de- 
pressive i11ness’06~1”7~216220. The discovery of these 
neuroendocrine abnormalities in melancholia, how- 
ever, was preceded by extensive study of regulatory 
mechanisms of neuroendocrine function in normal 
animals. These included in vitro’7~“~77~‘“‘~‘27 studies 
of the release of corticotropin releasing factor (CRF) 
from explanted hypothalamus’8,~~.~~,~6.~~~.~h~.~’~.~~~~ 
‘y.1,246 and in vivo studies of the physiology of the 
LHPA axis. One paradigm involved in vitro release 
of CRF from hypothalamic explants in response to 
various agonists. In general, catecholamines were 
found to generally be inhibitory and muscarinic agon- 
ists stimulatory of CRF secretion, both in vitro and in 
vivo7R,91.96,147~178*2’6. In vivo studies also indicated a 
muscarinic mechanism in the release of CRF and a 
noradrenergic mechanism in the inhibition of CRF 
and ACTH78,91.95,147.168.178.1'9.193.?46 Implantation of 
atropine crystals into the anterior hypothalamus in- 
hibits the release of vasopressin, ACTH. and 
CRFyh,135.14y and the adrenocortical response to sur- 
gical stress under ether anesthesia or to injection of 
arginine vasopressin. Krieger and Kriegeri4’ found 
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that atropine aborts the anticipated circadian rise in 
17-hydroxycorticosteroid plasma concentration in 
cats. Kaplanski and Smelik’35 reported implantation 
of atropine crystals into the anterior hypothalamus 
inhibited stress-induced ACTH secretion. These 
findings suggest that acetylcholine activates the 
LHPA axis under several conditions (baseline, 
stress, in response to diurnal changes, etc.). 
Regulation of the LHPA axis involves interactions 
among several neurotransmitter systems. Janowsky 
et al.‘*O, after reviewing the evidence, concluded that 
norepinephrine, endogenous opioids, and y-amino- 
butyric acid tend to inhibit whereas serotonin and 
acetylcholine tend to activate the axis. This simplifi- 
cation, however, is intended only as a guide. Seroto- 
nin, for instance, acts at several points along the 
LHPA axis120,148,259. Implantation of serotonin 
crystals at certain central loci induces elevated basal 
corticosterone levels in guinea pigs259 (i.e. activation 
of the axis) but inhibits ACTH release when placed in 
the dorsal hippocampus and amygdala“‘s. Moreover, 
its effects are contingent upon the state of the orga- 
nism - that is, whether the animal is at baseline, sub- 
ject to a stress, anesthetized, or at one point in its cir- 
cadian cycle rather than another. Serotonergic mech- 
anisms may in fact play a role in regulating circadian 
change in LHPA function, which are ‘contradictory’. 
For example, Parachlorphenylanine (PCPA)-in- 
duced depletion of brain serotonin elevates the 
morning decrement and prevents the evening rise in 
plasma corticosterone levels in unstressed ani- 
,,ls’50,259 
Physostigmine releases /I-endorphin in normal hu- 
mans31~49~203~206~207~210, but depressed patients show 
even greater increases3’~203*210. Risch et a1.31,82,203, 
2W*210 demonstrated that affective disorder patients 
exhibit concurrent behavioral and neuroendocrine 
hyperresponsiveness to physostigmine in comparison 
with normal and psychiatric control subjects. Physo- 
stigmine infusion also caused significantly greater 
plasma prolactin elevation in 14 affective disorder 
patients than in 15 non-affective psychiatric pa- 
tients’*‘. These increases correlated with cholinergic 
overdrive and with increases in negative affect when 
all 29 patients were grouped. Negative-affect was 
also correlated with the plasma /3-endorphin concen- 
tration in control subjects. However, patient sub- 
groups could not be compared with the normal sub- 
jects previously studied by these investigators be- 
cause the former received 33% less physostigmine. 
The authors suggest that the correlation of increases 
in negative affect with prolactin and plasma /I-endor- 
phin elevations following physostigmine infusion 
point to simultaneous involvement of central neuro- 
chemical mechanisms regulating affect, P-endorphin, 
and prolactin secretion. It is also possible, however, 
that these phenomena reflect a singe mechanism or 
result from two or more cholinergic systems operat- 
ing in parallel. 
Physostigmine infusion can cause escape from 
dexamethasone suppression31,49, a marker of the de- 
pressed state29. Davis and Davis35, questioning the 
specificity of this response, administered placebo and 
l-2.0 mg of physostigmine at a constant rate over 1 h 
to 17 subjects. They concluded it is not possible to 
identify an anterior pituitary hormone whose plasma 
level parallels changes in central cholinergic activity. 
The lowest dose of physostigmine did not alter plas- 
ma cortisol level and larger doses produced a ‘stress 
response’ marked by nausea and by elevations of cor- 
tisol, prolactin, and growth hormone concentrations. 
They proposed that nausea non-specifically elevated 
peripheral cortisol, prolactin, and growth hormone 
concentrations. 
Carroll et a1.31 gave oral syrup of ipecuacuanha to 
a male volunteer in order to test ‘stress response hy- 
pothesis’. The subject experienced ‘significant’ nau- 
sea and pallor and vomited twice. A month later, he 
received a physostigmine infusion regulated so as to 
avoid nausea. Both experiments were conducted af- 
ter dexamethasone was administered (the night prior 
to the experimental manipulation) 23.00-23.30 h, 
according to the standard protocol of the Michigan 
group . 29 The emetic did not cause escape of plasma 
cortisol from dexamethasone-induced suppression, 
despite having caused nausea and vomiting. Physo- 
stigmine, however, caused a major rise in plasma 
cortisol concentration without producing nausea. 
The subject rated the physostigmine experiment as 
being less noxious than the ipecuacuanha study. In a 
related study, methylscopolamine was given to block 
the peripheral effects of physostigmine. They admin- 
istered OS-l.0 mg of this agent i.v. using a pulse rate 
of 100lmin as an endpoint. Physostigmine nonethe- 
less produced elevation of plasma cortisol. Atropine 
pretreatment, by contrast, prevented the anticholi- 
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nesterase-induced escape from dexamethasone sup- 
pression. These findings suggest that physostigmine 
activates-a central cholinergic mechanism that in turn 
activates the LHPA axis and argues against the ‘non- 
specific stress-response’ hypothesis. 
Doerr and Berger49 also studied the effects of 
physostigmine on the LHPA axis during dexametha- 
sone suppression testing. Twenty-three normal sub- 
jects were given a 1.5 mg challenge of dexametha- 
sone at 23.00 h on Day 1: Methylscopolamine, 0.5 
mg, was given at 15.30 h on Day 2 to block peripheral 
affects of physostigmine. Escape was defined as a rise 
in plasma cortisol concentration to 25 pug/d1 or more 
at 16.00 h on Day 2. Three subjects escaped after re- 
ceiving 3 mg of the anticholinesterase, only one of 
these 3 experienced nausea. Ten subjects not re- 
sponding to 1.0 mg physostigmine failed to suppress 
when challenged one or two weeks later with 1.5 mg 
of the antichoIinesterase given by a slow infusion. 
Two of the remaining 10 suppressors escaped when 
2.0 mg of physostigmine was given. Nausea, dizzi- 
ness, and other symptoms characteristic of choliner- 
gic overdrive were more frequent at the higher doses. 
These data lend further support to the hypothesis 
that physostigmine activates a central muscarinic 
mechanism, thus causing escape from dexametha- 
sone suppression. 
4.1. Multilevel evafuation of the LHPA axis 
Developments in molecular biochemistry now al- 
low assessment of the LHPA axis at all levels. Pep- 
tides formed by the cleavage of a 31,000 dalton mole- 
cule, pro-opiomelanocortin, are co-released and in- 
teract with one another along the axis2,61.92,130.131. Se- 
lective cleavage of this molecule results in formation 
of ACTH and ~-endorphin, which are thus co-re- 
leased and co-regulated peptides. This knowledge 
has stimulated new questions that can be posed in 
clinical studies of LHPA function in patients with af- 
fective disorders. 
Drs. Stanley Watson and Huda Akil at Michigan, 
Alan Rosenbaum, formerly of Henry Ford Hospital 
in Detroit, and Dennis Charney of Yale University 
studied the release of cortisol, /?-endorphin@lipotro- 
pin at baseline and after dexamethasone challenge in 
47 patients with major depressive disorder, endoge- 
nous subtype and 16 controls with other psychiatric 
illnesses (personal communication from Dr. Stanley 
Watson). Subjects were diagnosed using the 
SADS244 and RDC”‘. Pre- and post-dexamethasone 
plasma cortisol and ~-endorphin~~-lipotropin plasma 
levels were measured in samples collected at around 
16.00 h in all subjects. Thirty-four depressed patients 
and 12 controls had samples collected at 20-min inter- 
vals between 15.30 and 16.30 h to allow determina- 
tion of intra-subject assay variance. Dexamethasone 
challenge was associated with lower P-endorphin//3- 
lipotropin levels, relative to baseline, in all but one 
control subject. Two fmol ~-endorphi~/~-Iipotro- 
phiniml, the post-dexamethasone plasma B-endor- 
phin//Xipotropin concentration maximizing predic- 
tive value for depression7”s7h, was selected as a cut- 
point. Ninety-five percent (95%) of the control sub- 
jects, compared to 41% of the depressives, demon- 
strated a decline or suppression of ,&endorphin/ 
/&lipotropin plasma concentration to below 2 fmoliml 
( 10-‘8/mI) on dexamethasone challenge. Twenty-two 
percent of the experimental group demonstrated 
non-suppression of cortisol release alone, and 39% 
showed non-suppression of P-endorphini@-lipotropin 
secretion but suppression of cortisol; 28% were sup- 
pressive of both, and 11% of neither ~-endorphin/ 
P-lipotropin nor cortisol. 
Is there a cholinergic defect at the limbic, hypotha- 
lamic, or pituitary level? The relationship of ACTH 
to ~-endo~hin/~-Iipotropin and plasma cortisol sug- 
gests several sites for studying the effects of choliner- 
gic challenge. Risch et al. ‘to documented a stoichio- 
metric relationship between ACTH and @-endorphin 
immunoreactivity thus indicating co-release in hu- 
mans in response to central cholinergic stimulation. 
They also showed that mood and behavioral changes 
produced by physostigmine are accompanied by ele- 
vations in both plasma /Gendorphin and cortisol con- 
centrations2~~.2~4,2~7.z~~. These findings suggest that 
physostigmine acts on central cholinergic mecha- 
nisms or relevance to affective disorders research. 
Measurements at fixed intervals of plasma corti- 
sol. ACTH, and ~-endo~hin/~-Iipotropin immuno- 
reactivity in normal human subjects and affective dis- 
order patients in response to different doses of 
physostigmine infused at a constant rate would be of 
particular interest. If dose-response curves for the 
release of P-endorphin and ACTH in response to 
pharmacologically induced central cholinergic over- 
drive in affectively ill patients fell to the left of those 
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of normal controls, the hypothesis of cholinergic su- 
persensitivity in depression would receive definitive 
confirmation. 
5. POLYSOMNOGRAPHIC DATA 
Polysomnographic abnormalities most frequently 
observed in patients with depressive disorders are (1) 
disturbances of sleep continuity or diminished sleep 
efficiency, (2) a reduction in d or (slow wave) sleep, 
(3) shortened REM latency, and (4) increased REM 
activity and density 62,66,67,83.84.154,155,157. nese abnor_ 
malities of primary97 or major depressive disorder, 
endogenous subtype243 can be produced by choliner- 
gic o~~~~~~~~98~1O~~105,122~128~129~136~139~169~170~232 and 
suppressed by cholinoceptor blockade221*255. 
Regulation of both the tonic (intra-stage) and 
phasic (having to do with the relationship of sleep 
stages to one another) aspects of sleep involves cho- 
linergic mechanisms 61.67,83,84.98,101-105.122,128,129,136-139, 
154.169.170*232. Anticholinesterases produce subjective 
disturbances of sleep continuity and vivid, terrifying 
dreams15.213.237. These complaints have polysomno- 
graphic correlates that facilitate study of cholinergic 
mechanisms involved in their pathophysiology. 
Physostigmine tends to awaken subjects when in- 
fused during REM episodes, and injection during 
non-REM sleep induces transition to REM sleep’36 
(as defined by cholinergically mediated generalized 
electrocortical activation, i.e., desynchronization). 
Induction of REM sleep by cholinergic agents is 
dose- and time-dependent 236. Physostigmine, 0.5 mg, 
given 5 or 35 min after sleep onset induced REM 
sleep, whereas, 1 mg infused 35 minutes after sleep 
onset aroused 3 of 5 subjects. Similarly, 5 of 7 sub- 
jects awoke when 0.5 mg physostigmine was infused 
during an REM episode. These observations suggest 
that cholinergic mechanisms have roles in mediating 
transitions from a state of relative behavioral and 
EEG inactivation (non-REM sleep) to one of in- 
creased propensity to awaken or become behavior- 
ally active and relative EEG activation (REM sleep). 
Hence, sleep is characterized by epochs of relative 
electrical and behavioral quiescence and activation 
and of low and high propensities to arousal. Non- 
REM sleep is marked by slowing and synchrony of 
the corticogram and REM sleep by EEG desynchro- 
nization. Thus, non-REM and REM sleep involves 
electrophysiological quiescence and arousal, respec- 
tively. These states, it should be noted, are on a con- 
tinuum. 
Gillin et a1.67 reported that physostigmine shortens 
the latency to onset of REM sleep without altering 
the duration of REM episodes. Sitaram et a1.234 
found that euthymic patients with primary affective 
illness demonstrated more rapid induction of REM 
sleep in response to cholinomimetic challenge than 
did control subjects, indicating phase advance of an 
&radian rhythm in affective disorder subjects. A 
similar abnormality is thought to be involved in the 
etiology of the shortened REM latency observed in 
primaryW or endogenous depression244. Thus, poly- 
somnographic changes induced by physostigmine 
suggest a phase advance resembling the derange- 
ment of the same &radian rhythm observed in de- 
pressive disease232. 
Concurrent induction of cholinkrgic overdrive and 
monoamine depletion causes extraordinary increases 
in the density and duration of REM sleep. Indeed, 
the combination of physostigmine and reserpine was 
once presented as a model of REM sleep139. This 
model is compatible with what we know about the 
physiology of sleep8.81,99,142*151,195. Anticholinergic 
agents and monoamine oxidase inhibitors both pow- 
erfully suppress REM sleep, and cholinergic activa- 
tion” antagonizes imipramine-induced suppression 
of REM sleep. These facts suggest that efforts to in- 
duce disturbances of REM sleep by modifying the 
physiology of cholinergic systems or cholinergic-mo- 
noaminergic interaction may be useful in studying 
the pathophysiology of sleep in the affective ill- 
nesses . 
Sitaram and associates85,233 reported that scopol- 
amine, given orally for 3 consecutive mornings and 
withheld on the 4th morning, was associated with de- 
creased REM latency and increased REM index and 
activity on the 4th night. Gillin et a1.85 applied to 
these data a mathematical model known to distin- 
guish the sleep of normal and depressives and found 
the scopolamine-associated sleep disturbance to be 
indistinguishable from the sleep of patients with pri- 
mary subtype 61 These findings are consistent with . 
reports that scopolamine12 and other centrally active 
anticholinergic agents, including tricyclics, induce 
muscarinic receptor up-regulation in rodent 
brain201,250*269 and cardiac tissue’80~*81. 
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A mathematical model of neuronal events regulat- 
ing the phasic aspects of sleep predicts the effects of 
antimuscarinic administration and withdrawal. Hob- 
son et aI.‘O’-‘Os and McCarley et al. ‘hy.i7u suggest that 
regulation of the phasic aspects of sleep involves in- 
teraction between cholinergic neurons of the pon- 
tine-gigantocellular-tegmental field (FTG) and nor- 
adrenergic neurons of the locus coeruleus (LC). 
Within the framework of this theoryiO”. referred to as 
the ‘reciprocal interaction mode’, neurons are 
labeled ‘excitatory’ if their depolarization affects 
EEG desynchronization, a correlate of behavioral 
arousal or excitation. The quanta1 release of acetyl- 
choline by FTG neurons, ceteris paribus, increases 
the rate of depolarization of both FTG and LC neu- 
rons; thus, these neurons are excitatory by conven- 
tion. In contrast to the cholinoceptive neurons of the 
FTG. noradrenergic neurons of the LC are ‘inhibito- 
ry’ because crescendoing of the mean rate of their 
discharges is associated with a decrease in EEG fre- 
quency and cortical synchronization. Electrophysio- 
logical studies indicate that the pertinent FTG neu- 
ronal population is subject to both autoregulation 
and regulation by a LC neuronal population. The 
converse is also true. The reciprocal interaction mod- 
el predicts an upsurge in the mean rate of FTG neu- 
ronal discharges at the onset of each REM episode 
and a concurrent dip in the mean frequency of LC 
neuronal depolarizations. The opposite occurs at the 
onset of non-REM episodes. 
This model has strong support. First, the temporal 
organization of FTG discharges with respect to the 
sleep-activity cycle is reciprocal to that of LC dis- 
charges. Second, each episode of REM sleep is tem- 
porally correlated with maximal mean frequency of 
FTG neuronal discharges. Third, each non-REM 
sleep period is associated with diminution of FTG ac- 
tivity and logarithmic build-up of LC activity. 
Fourth, histochemical and neurophysiological stud- 
ies indicate that FTG neurons contain and release 
acetylcholine and are autostimulated by this neuro- 
transmitter. Fifth, functional anatomic connections 
extend from the LC to FTG neurons and between LC 
neurons. Finally, immunohistochemical studies have 
disclosed varicosities staining for the presence of nor- 
epinephrine among FTG and LC neurons1”1.1”2~188. 
Prior to each REM episode, increased cholinergic 
outflow from the FIG to LC activates the latter, but 
the mean rate of FTG neuronal discharges increases 
simultaneously. This cholinergic push causes norad- 
renergic neurons within the LC to undergo a concur- 
rent increase in autoinhibitory input. The net result is 
a ‘turning off’ of the LC neuronal population. The 
timing can in principle be determined because it oc- 
curs at the hypothetically quantifiable threshold of 
aggregate FTG activity. Cholinergic overdrive can 
produce disturbances of sleep staging by inappropri- 
ately activating this process. 
In summary, data from naturalistic studies (occu- 
pational exposure to organophosphates)x’. human 
investigations8’,x4.17(),~~~.234.~3~ and animal research 
into the physiology and neurochemistry of sleep8’, 
')7.')8.101~105.1?1.1?2.1?9.136-139.180.188.20x.?33,~~s,~~~ are all 
consistent with the hypothesis that the pathophysio- 
logy of the sleep disturbance characterizing primary 
depressio# or major depressive disorder, endoge- 
nous subtype24”, mvolves muscarinic cholinergic sys- 
tem supersensitivity. 
6. SUPERSENSITIVITY OF AFFECTIVE DISORDER 
PATIENTS TO CHOLINERGIC CHALLENGE 
Affective disorder patients are more likely than 
normal and non-affectively ill psychiatric control sub- 
jects to exhibit exaggerated changes in mood, neuro- 
endocrine, and polysomnographic parameters in re- 
sponse to challenge with physostigmine or arecoline. 
Janowsky et al. ‘13 administered i.v. physostigmine to 
37 drug-free subjects diagnosed by the RDC’43. This 
sample included 10 patients with major depres- 
sion244, 7 with mania, 4 with schizoaffective disorder, 
and 14 with psychiatric illnesses without an affective 
component. Physostigmine, 0.022 mgikg, and place- 
bo were infused over 10 min on different days. Affec- 
tive disorder subjects had the greatest increases in 
self-reported measures of inhibition. The Brief Psy- 
chiatric Rating Scale (BPRS), depression subscale 
and the Profile of Moods States (POMS) also distin- 
guished subjects. POMS scores of affectively ill pa- 
tients showed the greatest increases in dysphoria, 
anxiety, hostility and fatigue. These subjects were 
rated as having a greater increase in depression on 
the BPRS depression subscale. Risch et al.“’ con- 
firmed these data using the same physostigmine 
dose, route of administration, and rating scales in a 
study of 14 subjects with major affective syndromes 
and 15 with ‘non-affective’ psychiatric diagnoses. 
Janowsky et al. recently found that affective disorder 
patients also exhibit exaggerated changes in autono- 
mically regulated cardiovascular variables upon cho- 
linergic challenge’*t. 
Affective disorder patients have augmented neu- 
roendocrine responses to cholinomimetic and physo- 
stigmine challenge. Physostigmine causes an in- 
crease in peripheral P-endorphin, ACTH, and corti- 
sol concentration in normal man both with and with- 
out concurrent dexamethasone challenge31~4g~207~210. 
As noted above, Risch et al.31,207,210 found that pa- 
tients with depressive disorders demonstrate neuro- 
endocrine hyperesponsiveness to physostigmine, 
i.e., greater increases in plasma /3-endorphin concen- 
tration compared to normal subjects and non-affecti- 
vely ill psychiatric patients203,205. This finding implies 
cholinergic system supersensitivity. 
Sitaram et al.234 reported that affective disorder 
patients in remission exhibit more rapid arecoline- or 
physostigmine-induced onset of REM sleep than nor- 
mal controls. It is not known, however, whether 
these subjects would have exhibited supersensitivity 
prior to their first affective episode, i.e., whether it is 
a trait marker or effect of illness. Many polysomno- 
graphic variables, however, have a genetic (or trait) 
component. Webb and Campbell265 obtained one- 
night polysomnographic recordings for 14 identical 
and fraternal young adult twin pairs. Sleep onset la- 
tency, awakenings during the night, number of 
changes in stage of sleep, and amount of REM sleep 
were significantly correlated for identical but not fra- 
ternal twin pairs. Nurnberger et al.ls4 tested the hy- 
pothesis that sensitivity to REM induction by areco- 
line is a heritable trait by measuring time to onset of 
the second REM period (REM,-REM2 interval) in 
twin pairs after placebo or arecoline infusion. The 
REM,-REM, induction interval was concordant for 
zygosity following the infusion of cholinomimetic but 
not placebo. These data suggest that the supersensi- 
tive polysomnographic responses to arecoline may be 
heritable, i.e. a trait. Thus, it is quite possible that su- 
persensitivity of affective disorder patients to phar- 
macologically induced cholinergic overdrive reflects 
a defect in cholinergic systems that predates devel- 
opment of the clinical features defining a mood disor- 
der. This issue, however, is far from resolved. 
The evidence that central cholinergic systems su- 
persensitivity contributes to the pathophysiology of 
the polysomnographic abnormalities of melancholia 
may provide the strongest support of the cholinergic 
hypothesis of depression. Perhaps the most impor- 
tant query for clinical investigation today is, ‘Do the 
polysomnographic features of major depression have 
premorbid antecedents that would imply abiding su- 
persensitivity of cholinergic systems?’ Longitudinal 
study of subjects at risk can answer this question. 
Study of the pathophysiology of sleep in affective 
disease may require a comprehensive approach, i.e., 
one using integrative models. Several central neuro- 
transmitter abnormalities may be contributory. For 
instance, serotonergic and noradrenergic mecha- 
nisms are involved in sleep physiology, and interac- 
tion between neurotransmitter systems may be caus- 
,143,46,48 
In conclusion, measures of behavioral, neuroendo- 
crine, and polysomnographic variables at baseline 
and in response to cholinergic challenge support the 
hypothesis that muscarinic cholinergic system super- 
sensitivity is either associated with or of etiologic sig- 
nificance in development of affective illness. 
7. MODERATE EVIDENCE FOR THE CHOLINERGIC 
HYPOTHESIS OF DEPRESSION 
The efficacy of antimuscarinic drugs in the treat- 
ment of depression, evidence of cholinergic-monoa- 
minergic antagonism in regulation of reward, punish- 
ment and hedonic capacity, effects of antidepressant 
and antimuscarinic withdrawal on behavior, and 
pharmacological properties of commonly abused 
substances provide moderate or possible evidence 
for the cholinergic hypothesis. These areas of study 
have untapped heuristic value, and their significance 
may transcend the strength of evidence they accord 
to hypothesis. 
8. THE RESPONSE OF AFFECTIVE STATES TO ANTI- 
CHOLINERGIC AGENTS 
Anticholinergic agents have euphorigenic’2,14* 
33.131,171,199,215,238 and antidepressantl,59,86.1*6,140,156. 
252,253 properties. Kasper et al.‘@ treated 10 severely 
depressed, hospitalized patients (classified using the 
International Classification of Disease (ICD)68, 
RDC244 and Newcastle Scale’@)) with an average 
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daily dose of 12 mg of biperidin for 30 days, A signifi- 
cant decline in the total Hamilton Rating Scale for 
Depression (HRSD)94 score (P < 0.001) was ob- 
served. HRSD subscales showing significant de- 
creases were retardation, agitation, depressed 
mood, initial insomnia, work and interest, and gas- 
trointestinal symptomatology. Tislow’s3 reported 
that anticholinergic drugs had short-term usefulness 
in treating depressed patients. Effectiveness extend- 
ing to one year was later reportedz5’. Symptoms re- 
sponding best to benzotropine. trihexyphenidyl, or 
biperiden were depression and anxiety in ‘neurotic’ 
and ‘psychotic’ patients. Jimerson and colleagues’26 
conducted a double-blind placebo-controlled study 
on the efficacy of trihexyphenidyl on the symptoma- 
tology of patients with major depression according to 
RDCZ4”. Subjects were randomly assigned to an 8- 
week trial of up to 20 mg of active agent or placebo. 
Clinical response was monitored by giving the Com- 
prehensive Psychiatric Rating Scale (CPRS)** week- 
ly on a blind basis. Sample size was not mentioned. 
Two subjects completing the S-week trial were re- 
ported to have ‘improved dramatically’, with CPRS 
scores declining from 29 to 13 and from 28 to 3. One 
subject from each group had to be withdrawn be- 
cause of poor response. Even at an average daily 
dose of 10 mg, trihexyphenidyl was tolerated well. It 
is not possible to assess the significance of this report, 
however, without knowing the sample size. 
The earliest studies of the effectiveness of anticho- 
linergic agents as antidepressants were flawed by 
failure to use standardized diagnostic criteria and 
clearly defined longitudinal measures of change in 
clinical state, but these ‘old’ studies did suggest that 
blockade of the muscarinic receptor produces antide- 
pressant effects. English” studied the effectiveness 
of N-ethyl-3-piperidyl-phenylcyclopentyl glycolate 
hydrochloride and N-ethyl-2-pyrrolidylmethyl-phen- 
ylcyclopentyl glycolate hydrochloride (Ditran) in a 
7:3 ratio in treatment of 25 psychiatric patients with 
various diagnoses. The same included 11 patients as- 
signed diagnoses of ‘depression’ (reactive, involutio- 
nal, and acute agitated). Improvement was defined 
by the clinician’s ‘global impression’ that the patient’s 
condition became less severe after single or repeated 
doses. The author concluded that Ditran had effec- 
tiveness as an antidepressant. Although other inves- 
tigators concurred that this drug is an effective anti- 
depressant’,5y,“6. some attributed its antidepressant 
properties a non-anticholinergic component of Di- 
tran. 
In conclusion, investigations suggest that agents 
with anticholinergic properties exert antidepressant 
effects, but the rigor of research design, diagnostic 
criteria and decision making, and measurement of 
outcome vary across studies. This area requires more 
attention. 
9. CHOLINERGICALLY INDUCED REDUCTION OF 
HEDONIC BEHAVIOR 
Systemically and intracerebrally administered an- 
ticholinesterases and muscarinic agonists decrease 
drive reduction behavior in animals5~26~“0~y1~176~185~ 
187,1y1~217,218,245. Though not providing a literal model 
of anhedonia, which after all involves subjective 
components, these agents do cause sufficiently stable 
behavioral changes to allow multiple measurements 
of behaviors in animals paralleling acts that would 
have hedonic significance in man. This strategy de- 
mands formulation of operational definitions of tar- 
geted behaviors consonant with the purposes of the 
investigators and dictates of the experimental situa- 
tion. Such definitions must clarify the limits and na- 
ture of these behaviors, measure their crucial aspects 
(intensity, frequency, etc.), and assess the capacity 
of pharmacological manipulations to produce devia- 
tions of these variables from baseline. 
Studies assessing cholinergic contributors to the 
physiology of hedonic capacity are plagued by un- 
identified sources of variance and confounding varia- 
bles. First, there are many cholinergic systems 
(though most fibers stem from the nucleus magnus 
basalis). Second, effects of cholinergic agents are re- 
lated to route of administration and when applied di- 
rectly to brain nuclei, locus of application. Third, an- 
atomic distinctiveness implies neither functional in- 
dependence nor functional dependence. Interaction 
or mutual interdependence of neuronal populations 
may complicate experimental efforts. Olds, in his 
classic articlels6, concluded that structures underly- 
ing primary reward are located in a midline network 
extending from the midbrain cephalad to the hypo- 
thalamus, midline to the thalamus and thence to sub- 
cortical and cortical portions of the rhinencephalon. 
Those structures, he asserted, were distinct from 
those mediating the effects of primary punishing 
events. Neural mechanisms mediating the effects of 
rewarding and punishing events, however, are 
known to interact; rewarding events reduce sensitivi- 
ty to punishment and vice versa. These anatomical 
and functional distinctions are essential. Application 
of a neurotransmitter to the reward system may in- 
duce drive-reduction behavior or reward, whereas its 
injection into an area mediating punishment may di- 
minish the frequency of the same behavior or me- 
diate the ‘experience’ of punishment. Caution must 
therefore be exercised in interpreting data from mi- 
croinjection studies. Finally, the organismal re- 
sponse to systemic administration of a drug may rep- 
resent summation of central and peripheral effects, 
and peripheral effects can alone alter behavior. 
Domino and Olds’* studied the effects of physo- 
stigmine and neostigmine on self-stimulation behav- 
ior in rats with chronic hypothalamic electrode im- 
plantation. Doses of neostigmine equimolar to 
physostigmine caused significantly less reduction in 
and shorter periods of decreased self-stimulation be- 
havior. Overstreet et al.ry’ studied the effects of sys- 
temically administered amphetamine and pilocar- 
pine on ingestive behavior in normal and chronically 
DFP-treated rats. Tolerance to DFP was marked by 
chronically low acetylcholinesterase levels. The sym- 
pathomimetic diminished food intake in both groups 
equally, but the cholinomimetic failed to produce a 
reduction in food intake in anticholinesterase-treated 
animals. These observations suggested that choliner- 
gic mechanisms are involved in inhibiting ingestive 
behavior and that they are subject to development of 
subsensitivity. 
Olds and Domino’** studied the effects of subcuta- 
neously administered nicotinic and muscarinic agents 
on self-stimulation in animals with electrodes im- 
planted into the lateral-posterior hypothalamus. 
Physostigmine and arecoline both caused depression 
of this behavior that was blocked by scopolamine and 
augmented by mecamylamine. Methylscopolamine 
was clearly less effective than scopolamine in this re- 
gard. Olds lg7 also reported that scopolamine antago- 
nized the inhibitory effects of physostigmine and 
chlorpromazine on drive reduction behavior. The 
chlorpromazine-scopolamine antagonism may be 
due to dopaminergic-cholinergic reciprocity or 
counterbalance that parallels nigrostriata13,10 and 
mesolimbic dopaminergic-cholinergic interactiona. 
Decreased cholinergic tone can produce a functional 
increase in dopaminergic activity. 
Stark and Boyd 245 found that physostigmine but 
not neostigmine caused a depression in the frequency 
of intracranial self-stimulation in dogs with elec- 
trodes implanted into the medial mamillary nucleus 
of the hypothalamus. Atropine but not methylatro- 
pine pretreatment prevented this. Cholinesterase in- 
hibition paralleled the reduction in self-stimulation. 
This report is also consistent with the hypothesis that 
activation of central cholinergic mechanisms produc- 
es decreases in drive reduction or rewarded behav- 
iors. 
Russell et a1.217,218 studied behavioral correlates of 
tolerance to DFP. Diminished acetylcholinesterase 
activity was used as biochemical evidence of chronic 
cholinergic overdrive. Food and water intake were 
measured during 8 days of baseline (pre-drug) obser- 
vation, a DFP administration phase involving a large 
loading dose and periodic boosters until targeted be- 
havioral variables returned to baseline, and a with- 
drawal or recovery period. DFP treatment caused 
both food intake to decrease, but this parameter 
tended to return to baseline by the third day. Water 
intake showed a great decrease and required 13 days 
to recover. DFP withdrawal caused a rebound in- 
crease in consumption. These findings are also con- 
sistent with the h~othesis that central chohnergic 
mechanisms subserve aspects of drive reduction be- 
havior and are subject to modification by perturba- 
tion of cholinergi~ neurons. Peripheral effects of an- 
ticholinesterase treatment cannot be excluded, but 
one would expect a peripheral component to be non- 
specific, i.e. to affect water and food consumption 
similarly. The longer duration required for water 
consumption to return to baseline, 13 days as op- 
posed to 3 days for food intake, suggests that if a pe- 
ripheral component is pertinent it pertains to the lat- 
ter. 
Sidman230 reported that atropine disrupted shock 
avoidance responses and that behaviors rarely ob- 
served (if at all) under normal circumstances result 
from its use. Methylatropine ineffectively or weakly 
mimicked atropine. He concluded that atropine in- 
hibited a cholinergic system that antagonizes another 
neurotransmitter system that activates behaviors 
punished by shock. This hypothesis that parallels in 
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theory of general behavioral (psychomotor, attentio- 
nal) activation and mood regulation developed by 
Dilsaver and Greden4s. 
Carlton25*26 studied the effects of cholinoceptor 
blockade and amphetamine on animals conditioned 
to press right and left-sided levers alternately in or- 
der to be reinforced by delivery of a small quantity of 
milk. Scopolamine and catecholaminergic activation 
both resulted in perseveration. Is non-reward a type 
of punishment? In operant’ paradigms non-reward 
and punishment have the same effect viz. extinction. 
Thus, cholinergic blockade can be conceived ceteris 
paribus as either diminishing the intensity of punish- 
ment or making non-punishing what is normally re- 
garded as punishment, assuming we are not dealing 
with a randomness caused by drug toxicity. Carl- 
ton25,26 hypothesized that diminished cholinergic 
tone and increased catecholaminergic activity pro- 
duce similar results and that antimuscarinics and 
catecholaminergic agents have additive or synergistic 
effects. He defined a range of ‘subthreshold’ reduc- 
tions in cholinergic function by administering small 
amounts of atropine to rats trained on an operant 
shock-avoidance schedule. Amphetamine. 0.25 
mg/kg, also failed to increase responding. Simulta- 
neous administration of these subthreshold doses of 
atropine and amphetamine, however, produced 
marked increases in non-rewarded responses which 
were not predicted by study of each agent separately. 
The frequency of non-rewarded responses increased 
with the dose of amphetamine or atropine. Methyla- 
tropine did not substitute for atropine. In conclusion, 
a central muscarinic mechanism and monoaminer- 
gic-cholinergic interaction were implicated in the 
regulation of operantly conditioned shock avoidance 
behavior. In effect, the ‘experience’ of punishment 
was altered by the various manipulations. 
Anhedonia is central to some concepts of depres- 
sion’60 and a salient symptom in many patients with 
recurrent depressions. Animal models of hedonic im- 
pairment could therefore be quite valuable in the 
study of melancholia. Development of such a model, 
however, will not come easily. Hedonia (hedonic ca- 
pacity) is a complex phenomenon. It can be defined 
operationally or conceptually divided into compo- 
nents, but it is always many things. It encompasses 
subjective, psychological, somatic, neurochemical, 
and behavioral elements. Animal models of hedonia 
or anhedonia are unavoidably reified approximations 
of a human reality. However. even limited models 
may allow us to test hypotheses by isolating quanti- 
fiable variables relevant to understanding human 
drive reduction behavior. The fact that extending 
generalizations or inferences drawn from animal data 
to the experience of man involves anthropomorphiz- 
ing neither invalidates nor seriously impugns such 
models; it is simply evidence of limitation of models 
in this area. 
Animal models of hedonia, which would be based 
on behavioral and neurochemical theories pertaining 
to mechanisms mediating drive reduction behavior, 
should be valuable in directing study of the pathophy- 
siology of anhedonia in melancholia. Behavioral and 
pharmacological approaches can direct study of the 
neuroanatomy, neurochemistry, and neurophysiolo- 
gy of normal and abnormal hedonic capacity. The hy- 
pothesis that the ‘central pain’ associated with melan- 
cholia is associated with direct or indirect inhibitory 
effects on neural substrata subserving hedonia and 
involves aberrations of central cholinergic system is 
testable in animals without succumbing to reductio- 
nism. 
10. DRUG WITHDRAWAL DATA 
In general, chronic treatment with antimuscarinic 
agents elicits neuronal and behavioral responses 
characteristic of other substances that produce de- 
pendence. Antimuscarinic agents produce tolerance; 
the effects of withdrawal in patients being treated for 
Parkinson’s disease or neuroleptic-induced extra- 
pyramidal dysfunction lo8 include gastrointestinal dis- 
tress, a flu-like syndrome, anxiety, sleep disturb- 
ance, and rebound exacerbation of motor dysfunc- 
tion. 
Withdrawal of tricyclic antidepressants precipi- 
tates discrete syndromes. The most common are gen- 
eral somatic or gastrointestinal distress accompanied 
by anxiety or agitation, sleep disturbance character- 
ized by excessive and vivid dreaming and initial or 
middle insomnia, akathesia or parkinsonism, and 
psychic or behavioral activation on a continuum to 
mania’. Dilsaver and associates46~48*176,‘s” concluded 
that withdrawal precipitated cholinergic overdrive 
accounts for most antidepressant withdrawal phe- 
nomena, though they emphasized that some are al- 
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most certainly due to disturbances of cholinergic- 
monoaminergic interaction43,4s-47. The ‘cholinergic 
overdrive hypothesis’43 is the thesis that withdrawal 
of antidepressants with antimuscarinic properties 
triggers increased cholinergic activity at critical pe- 
ripheral and central loci and thence symptomatolo- 
gy. These loci include the gastrointestinal system and 
nigrostriatal, mesocortical, and mesolimbic tracts. 
The hypothesis is supported by the facts that (1) tri- 
cyclics are muscarinic antagonists4~13~202,241,247,2s4, (2) 
antimuscarinic agents produce tolerance and, upon 
withdrawal, hyperexcitability of cholinergic sys- 
tems40.73’l’0,22s, (3) antidepressant withdrawal symp- 
toms respond to anticholinergic drugs, and (4) ami- 
triptyline and desipramine produce cholinergic sys- 
tem up-regulation and supersensitivity in rodent 
brain and heart, respectively. 
Tricyclic-induced supersensitivity of cholinergic 
systems is evidenced by differences in pupillary re- 
sponsivity to a cholinomimetic before, 7 days after, 
and 21 days after starting desipramine in depressed 
subjects 40-228 Twenty-one days of desipramine treat- 
ment, but not 7, were associated with an enhanced 
miotic response to pilocarpine. Scopolamine causes 
an increased density of muscarinic receptor binding 
sites in rat hippocampus. Many other investigators 
have confirmed this effect of classic antimuscarinics. 
Rehavi et a12” reported that 21 days of amitriptyline 
administration, but not 7, produced an elevation in 
the density of muscarinic receptor ligand binding 
sites in mouse forebrain. Goldman and Erickso# 
also observed amitriptyline produced up-regulation 
of muscarinic receptors in rat brain. Normura et a1.18’ 
reported that desipramine, 10 mg/kg twice daily for 
10 days, induced a significant increase in maximum 
muscarinic radioligand binding sites in rat myocardi- 
urn. These investigators also found that desipramine 
induced supersensitive physiological and biochemi- 
cal responsiveness of the myocardium to acetylcho- 
line. D&aver and Snider41 recently observed that 
chronic tricyclic treatment produced supersensitivity 
to oxotremorine in rats as inferred from differences 
in cholinomimetic-induced hypothermia before and 
after amitriptyline treatment. 
The ‘cholinergic overdrive hypothesis’ is subject to 
examination using neuroendocrine strategies. We 
predicted, for example, antidepressant withdrawal 
would produce non-suppression to dexamethasone 
challenge . 42 To test this hypothesis, we assessed the 
integrity of the LHPA axis by measuring its capacity 
to respond appropriately to dexamethasone chal- 
lenge before and at one or more points after antide- 
pressant withdrawal. Post-dexamethasone plasma 
cortisol concentrations and HRSDg4 scores were se- 
rially monitored in 15 subjects being withdrawn from 
tricyclics or a tetracyclic (maprotiline) during the 
first two weeks of hospitalization on the Clinical 
Studies Unit for Affective Disorders at the Universi- 
ty of Michigan (CSU). A control group was com- 
prised of 9 endogenously41*42 depressed patients who 
were drug-free on the CSU. ‘Drug-free status’ is de- 
fined as 14 or more days removed since receiving the 
last dose of psychotropic medication. Control sub- 
jects had become drug-free within 4 days of admis- 
sion. All subjects were inpatients and diagnosed 
using the SADS244 and RDC243 as having major de- 
pression, endogenous subtype. 
Post-dexamethasone plasma cortisol levels were 
significantly elevated during the drug-withdrawal 
phase. Twelve subjects had higher post-dexametha- 
sone plasma cortisol levels during the withdrawal 
than during the post-withdrawal phase. Ten of 14 
(71.4%) of these subjects had a positive DST during 
the lbday withdrawal phase, compared to 2 of 9 
(22.2%) control subjects (P = 0.03, Fischer’s exact) 
during the first two weeks of their hospitalization. 
These differences in the frequencies of positive DSTs 
and absolute post-dexamethasone plasma cortisol 
levels did not persist after the withdrawal subjects 
became drug-free. 
No differences in HRSDg4 scores were detected at 
baseline or over the course of the study, nor did 
weight change differ significantly between groups. 
This retrospective study did not establish the role of 
antidepressant withdrawal-induced cholinergic over- 
drive in the generation of abnormal responses to 
dexamethasone challenge. It was, however, consis- 
tent with hypotheses regarding effects of antidepres- 
sants on cholinergic systems. Effects of antidepres- 
sant withdrawal on the LHPA axis must now be stud- 
ied using a design involving random assignment of 
subjects to multiple daily doses of a tricyclic, anti- 
muscarinic and placebo. 
In principle, medical treatments or recreational 
drugs that supersensitize muscarinic cholinergic sys- 
tems should increase the probability of a subject’s de- 
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veloping depressive episodes. Marijuana may be a 
good example. Cannabis produces tachycardia, dry 
mouth, suppression of REM sleep, a trend toward 
slowing of the electrocorticogram, short-term memo- 
ry deficiencies, and other effects characteristic of 
centrally active anticholinergic drugss4,“‘. Layman 
and Milton”’ verified that cannabinoids decrease the 
release of acetylcholine at muscarinic junctions. As- 
suming sufficient potency, dose, and duration of 
treatment, postsynaptic muscarinic receptor up-reg- 
ulation and cholinergic system supersensitivity would 
be expected to occur. 
Animal studies and clinical reports are consistent 
with the hypothesis that cannabinoids render central 
cholinergic systems supersensitive. El-Yousef et 
al.“, (Cf. Section 3) found that chronically intoxi- 
cated marijuana users developed profound depres- 
sion when challenged with physostigmine. Further- 
more, LI”-THC potentiates the toxicity of physostig- 
mine in rats. Dilsaver et a1.44 observed a withdrawal- 
induced state of cholinergic overdrive in an 18-year- 
old woman who discontinued thiothixene and benzo- 
tropine abruptly. Both of these psychotropics are an- 
timuscarinic”. We later learned that she had chroni- 
cally abused marijuana. Though she lacked a person- 
al and family history of a depressive disorder, she de- 
veloped a severe depressive syndrome with definite 
‘anticholinesterase-like’ symptomatology. Symp- 
toms included tearfulness, agitation, ‘extreme mus- 
cle tenseness’, behavioral withdrawal, apathy, de- 
creased verbal production, apprehensiveness, psy- 
chomotor retardation, severe insomnia or near sleep- 
lessness for about 3 days, slowing of thought pro- 
cesses, poor self-care, fear of losing her mind, nau- 
sea, vomiting, anorexia, and diarrhea - all features 
of endogenous depression. This syndrome responded 
to high dose oral atropine sulfate, 1.2 mg every 4 h, 
without development of noteworthy side-effects. We 
concluded that cannabis abuse induced muscarinic 
cholinergic system supersensitivity and that psycho- 
tropic withdrawal triggered cholinergic overdrive. 
In conclusion, drugs blocking postsynaptic musca- 
rinic receptors (belladonna alkaloids, synthetic 
agents resembling atropine, tricyclics, or diminishing 
the release of acetylcholine centrally (opiates, canna- 
binoids, ethanol, barbiturates) are apt to produce 
central cholinergic system up-regulation and super- 
sensitivity. These agents might be safely used to 
model aspects of affective illness, as discussed in Sec- 
tion 1.5. Such a strategy would require the measure- 
ment of behavioral, physiological (e.g.. neuroendo- 
crine and polysomnographic parameters), and bio- 
chemical variables before, during. and after drug 
treatment. Concepts and methods essential to using 
these agents in studying (modeling) the pathophysio- 
logy of affective disorders are reviewed elsewhere”. 
Il. DRUG ABUSE DATA 
Euphorigenic properties2’5.Z38*252,253 render anti- 
muscarinic agents substances of abuse. Other eupho- 
riants including marijuana, a1coho127.200.23Y.2~y, barbi- 
turates262-264,283, and ~p~~tesSl~124~125~lY5~222. show a 
similar capacity to antagonize cholinergic systems. 
Marijuana, ethanol, and barbiturates are all in- 
hibitors of acetylcholine release, whereas classic an- 
timuscarinic agents, and tricyclic antidepressants di- 
rectly block the postsynaptic muscarinic receptor. 
Either event can cause supersensitization of choliner- 
gic networks. 
Marijuana abuse has been implicated in the gene- 
sis of ‘hypomanic-like’ syndromes158~2’2. Cannabi- 
noid-induced decreases in the release of acetylcho- 
line could account, at least in part, for this phenome- 
non. Reduced cholinergic activity produces euphoria 
and hyperactivity, cardinal features of hypomania. 
Carmichael and Israel12’, studying the propensity of 
ethanol to inhibit electrically stimulated release of 
several neurotransmitters from rat cortical slices, 
found it to be a potent inhibitor of acetylcholine re- 
lease; the IC,, of ethanol for the inhibition of acetyl- 
choline release was only 34-3.5% that for mono- 
amines. Acetylcholine, at a blood ethanol concentra- 
tion marking moderate to severe intoxication, 
showed the greatest reduction in release of all neuro- 
transmitters screened. Tabakoff et a1.‘4y observed 
that 7 days of ethanol administration produced a 
115125% increase in specific (3H]QNB binding in 
hippocampal and cortical homogenates derived from 
mice. Ethanol was undetectable in blood 8 h after its 
discontinuation but physical dependence was demon- 
strated by seizures during the first 24 h of abstinence. 
Smith239 gave ethanol, 7% by volume in water, to 
mice for 8 days. This regime produced severe depen- 
dence as evidenced by hyperactivity (e.g.. whole 
body tremor) and convulsions upon routine handling. 
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A cholinergically enriched synaptosomal fraction 
from brain demonstrated a 128% increase in specific 
radioantonist ([3H]QNB) binding. Rabin et aL2” 
also found that ethanol, 7% by volume, increased the 
density of [3H]QNB binding sites in hippocampus 
and cerebral cortex. 
Treatment with an agent diminishing the quanta1 
release of acetylcholine induces supersensitivity of 
cholinergic systems. Wahlstrom264 reported, using 
choline-induced seizures as an index, that chronic 
barbital treatment induced cholinergic system super- 
sensitivity. Wahlstrom and Nordberg263 observed 
that velocity of choline uptake is increased 12 days af- 
ter the discontinuation of barbital in rats. This pa- 
rameter is related to the rate of acetylcholine synthe- 
sis and utilization. Nordberg and Wahlstrom’82 found 
that treatment of rats with atropine early in the post- 
barbital withdrawal phase significantly decreased the 
morbidity of barbiturate withdrawal. When the rats 
were sacrificed 81-83 days after barbital disconti- 
nuation, a reduction in brain weight was found in 
those animals receiving saline instead of atropine. 
The concentration of endogenous acetylcholine was 
decreased in barbital-treated rats. This variable bore 
a relationship to reduction in brain weight. Wahl- 
Strom and Ekwa11262 showed that an exaggerated hy- 
pothermic response to pilocarpine occurs concomi- 
tant with the development of tolerance to a barbitu- 
rate. Nordberg and Sundwall’83 found that a single 
dose of pentobarbital decreased acetylcholine turn- 
over. Domino and Wilson5’ showed that pentobarbi- 
tal inhibited the utilization of acetylcholine. Anes- 
thetizing doses completely blocked the hemicolinum- 
3 induced depletion of brain acetylcholine in rats, im- 
plying a blockade of acetylcholine release. Schuberth 
et a1.226 corroborated this finding. All of these consi- 
derations suggest that barbiturates acutely decrease 
the activity of cholinergic systems, presumably by di- 
minishing presynaptic release of acetylcholine. This 
diminution would promote supersensitivity of cholin- 
ergic networks and provide a pathophysiological ba- 
sis for development of cholinergic overdrive asso- 
ciated with barbiturate withdrawal. 
Signs and symptoms of opiate withdrawal include 
coryza, sialorrhea, nausea, vomiting, anorexia, diar- 
rhea, myalgias, sleeplessness, anxiety, agitation, irri- 
tability, headaches, dizziness, tachycardia, and hy- 
pertension. Anticholinesterases and tricyclic antide- 
pressant withdrawal produce similar clinical fea- 
tures3g.43. Withdrawal of these drugs may induce 
states of cholinergic overdrive, though this is not to 
suggest that these manipulations lack other conse- 
quences essential to their effects. There is in fact evi- 
dence that opiate withdrawal involves a cholinergic 
component. Several investigators have reported that 
narcotic agonists block release of acetylcholine from 
cortex51 and guinea pig ilium’25,‘g5*222. The meaning 
of this finding is disputed 124~125~1g5 because of failure 
to demonstrate increased brain acetylcholine con- 
centration during the withdrawal phase or elevation 
of the baseline concentration of acetylcholine at criti- 
cal central loci after opiate treatment. This criticism, 
however, is based on the faulty assumption that treat- 
ment with pharmacological agents diminishing the 
quanta1 release of acetylcholine must produce in- 
creased release of acetylcholine during drug withdra- 
wal in order to cause a withdrawal syndrome. Cholin- 
ergic, monoaminergic, peptidergic, and GABAergic 
systems interact; perturbations of cholinergic net- 
works induce changes in other neurotransmitter sys- 
tems and vice-versa. These interactions must be tak- 
en into account when studying normal and abnormal 
cholinergic mechanisms. D-Amphetamine enhances 
utilization of acetylcholine in brain’63, which might 
lead to the supposition that D-amphetamine causes 
dysphoria, not euphoria. When the mechanisms un- 
derlying D-amphetamine’s actions are understood, 
however, there remains no inconsistency with a theo- 
ry positioning cholinergic system overdrive as a hall- 
mark of dysphoric states, since amphetamine can be 
properly regarded as an agent that produces both re- 
lease of acetylcholine and euphoria. 
Dilsaver and Greden48 developed the idea of ‘cho- 
linergic monoaminergic interaction’ in the pathophy- 
siology of affective illness and presented it as a theo- 
retical principle that might explain the phenomenolo- 
gy, LHPA axis dysfunction, polysomnographic ab- 
normalities, and rapid changes in clinical state ob- 
served in rapidly cycling bipolar patients. For the 
purpose of illustration, consider the ‘central pain’ of 
melancholia3’, a phase referring to a vague, inexpli- 
cable, and overpowering agony characterizing the 
experience of the melancholic. Its severity may be as- 
sumed to be a function of two complex variables, 
each variable containing within itself multiple addi- 
tional terms; these subvariables correspond to the 
myriad of factors that combine to determine the ulti- 
mate status of cholinergic and monoaminergic sys- 
tems. The cholinergic and monoaminergic systems, 
however, stand in a dynamic relationship marked by 
perpetual interaction. interregulation, and autoregu- 
lation. Thus, increased release of acetylcholine may 
be associated with euphoria if the status of monoam- 
inergic systems relative to cholinergic systems meets 
certain contingencies. Similarly, opiate-induced su- 
persensitivity of muscarinic cholinergic systems 
could precipitate cholinergic overdrive upon drug 
discontinuation without withdrawals increasing the 
release of acetylcholine. The amount of neurotrans- 
mitter release is but one of many subvariables defi- 
ning the one complex variable that describes the sta- 
tus of cholinergic systems. 
Amphetamine activates the reticular activating 
system (RAS)164. Electrical or pharmacological stim- 
ulation of this network causes release of acetylcho- 
line at the cortex’32,1h7.248 , an event essential to the 
induction of EEG desynchrony, the classic EEG cor- 
relate of alertness. The RAS also activates hmbic 
structures mediating behavioral arousa14* - that is, 
stimulation of the RAS has indirect effects upon lim- 
bit nuclei which are dependent on anatomic continui- 
ty between these sites. But D-amphetamine also acts 
directly on the mesolimbic system and thereby ex- 
cites the ascending activating system. Similarly, it in- 
directly mobilizes limbic monoaminergic systems 
which regulate mood and psychomotor function, but 
it also activates these nuclei directly. 
Observations that opiate withdrawal produces 
cholinergic overdrive-like symptoms though opiate 
treatment does not increase brain acetylcholine con- 
centration or release of acetylcholine can be ex- 
plained using the same line of reasoning. The as- 
sumption that there should be a measurable increase 
in brain acetylcholine concentration in the context of 
opiate treatment disregards the principle of ‘autore- 
gulation’ of acetylcholine synthesis. The synthesis of 
acetylcholine is sensitive to the intraneuronal con- 
centration of acetylcholine. Acute and chronic opiate 
administration can have opposite effects on acetyl- 
choline synthesis and acetylcholine concentration. 
Protracted drug treatment may not produce rises in 
brain acetylcholine concentration because of the op- 
eration of compensatory mechanisms. After an acute 
or initial phase, the neuron may respond to chronic 
decreased release of or need for acetylcholine by di- 
minishing its synthesis. This explanation accords with 
observations of the ways in which cholinergic neu- 
rons regulate the intraneuronal concentration of ace- 
tylcholine. 
A solution to the ‘problem’ posed by the finding 
there is no increase in the release of acetylcholine 
during the opiate withdrawal phase requires precise 
definitions of ‘up-regulation’ and ‘supersensitivity’. 
The term ‘up-regulation’ means that there is a statis- 
tically significant increase in the density of specific li- 
gand binding sites (B,,,) on a given type of receptor. 
Everything else being equal, up-regulation is asso- 
ciated with supersensitivity to an agonist. In some cir- 
cumstances, however, up-regulation may occur with- 
out development of supersensitivity. ‘Supersensitivi- 
ty’ refers to enhanced behavioral, physiological or 
biochemical responses to endogenous or exogenous 
agonists. Supersensitivity can be due to several 
mechanisms that can be categorized according to lo- 
cation of neuronal modifications46. First, intra-neu- 
ronal events can potentiate effects of agonists on 
neurons with normal receptor density. For example, 
phosphodiesterase inhibitors act by inhibiting the de- 
struction of cyclic-AMP in adrenergic neurons. Sec- 
ond, enhanced release of an endogenous agonist can 
produce supersensitivity. Increased availability of a 
neurotransmitter in a releasable pool provides the 
basis for exaggerated release of catecholamine upon 
amphetamine challenge. Amphetamine-induced hy- 
pertensive crisis in patients being treated with mono- 
amine oxidase inhibitors is an example of this phe- 
nomenon. Third, supersensitivity can result from in- 
creased effectiveness of agonist-receptor coupling 
consequent to receptor modification or to intra- 
membrane or intra-neuronal changes that amplify 
the effects of agonist-receptor binding. Enhanced 
effectiveness of agonist-receptor coupling in pro- 
moting ionic flux through ion channels is illustrative. 
The benzodiazepine receptor complex is a good ex- 
ample. This complex includes a site for binding y- 
aminobutyric acid and a chloride channel’. and the 
effectiveness of an agonist binding to the benzodiaze- 
pine receptor is dependent on the functional status of 
the other elements forming the complex. 
Let us consider the nature of narcotic withdrawal 
states in light of these points. Suppose that opiate 
treatment shifts the dose-response curve for devel- 
303 
opment of some symptoms by acetylcholine to the 
left. Such a shift would occur if opiate treatment 
caused supersensitivity of cholinergic systems. 
Opiate-induced cholinergic system supersensitivity 
could provide a pathophysiological basis for devel- 
opment of cholinergic overdrive when opiates are 
withdrawn; a withdrawal-associated increase in ace- 
tylcholine release would not be required. 
In conclusion, opiates may modify dholinergic sys- 
tems, monoaminergic mechanisms, or cholinergic- 
monoaminergic interaction, and the pathophysiology 
of narcotic withdrawal states could be directly re- 
lated to these changes. The role of cholinergic mech- 
anisms in mediating the effects of opiates and their 
withdrawal warrants further study. The relationships 
of abusable substances to cholinergic systems in- 
volved in the regulation of mood, affect, psychomo- 
tor function, and hedonia could also be heuristically 
important48. Such substances may be useful in the 
study of mechanisms related to subjective elements 
and objectively measured correlates of the affective 
disorders. 
12. TENTATIVE EVIDENCE FOR THE CHOLINERGIC 
HYPOTHESIS: BRAIN MUSCARINIC RECEPTOR AL- 
TERATIONS IN SUICIDE VICTIMS 
Meyerson and associates’73 measured the B,, of 
ligand binding to the muscarinic and #I-adrenergic re- 
ceptors and the density of imipramine binding sites in 
brain tissue obtained from 8 victims of violent suicide 
and control subjects dying suddenly in automobile 
mishaps or violent homicides. They found increases 
of 47% and 35% in [3H]QNB and [3H]imipramine 
binding sites, respectively, in the suicide group as 
compared to the control group. The density of [3H]di- 
hydroalprenlol binding sites, an index of /3-adrener- 
gic receptor density, did not distinguish groups. 
Agonists and antagonists, such as tricyclic antide- 
pressants, can interfere with binding experiments. 
The investigators therefore measured imipramine, 
desipramine, and amitriptyline levels in cortical tis- 
sue, using an assay sensitive to 50 pglmg of tissue, in 
an effort to determine whether recent tricyclic treat- 
ment might have been a confounding variable. Anti- 
depressants were not detectable. This finding does 
not, however, exclude the possibility of antidepres- 
sant effects on the experimental variables. 
Post-mortem studies have inherent limitations. 
These limitations include, but are not restricted to, 
difficulties in gathering accurate psychiatric and 
medical histories as well as lack of information on 
substance abuse and use of centrally active pharma- 
cologic agents used in treating primary neurological, 
medical and psychiatric diseases. These confounding 
variables can complicate data interpretation and con- 
tribute to false positive and negative results. More- 
over, sample bias may interfere with post-mortem 
studies, especially those based on small samples. Un- 
identified sources of sample bias would occur if sui- 
cide victims contained either an insufficiency or ex- 
cess of individuals with affective disorders. Such bi- 
ases could contribute to chance rejection of a true ex- 
perimental hypothesis (type I error) or to erroneous 
acceptance of the null hypothesis (type II error). 
Power of statistical tests may limit the meaning of a 
negative suicide study. The power of a test is the 
probability that it will detect, assuming random sam- 
pling and absence of sample bias, a difference be- 
tween groups or categories when in actuality there is 
a difference. Low statistical power raises the proba- 
bility of type II errors. Everything else being equal, 
the power of tests increases with sample size. A posi- 
tive report based on the study of small samples can be 
suggestive, but a negative report speaks only weakly 
against the null hypothesis. The positive result re- 
ported by Myerson et al. 173, based on a sample of 8, 
may be important. This conclusion, however, would 
assume that the two groups (suicide and homicide/ac- 
cident victims) were quasi random samples of the 
populations the investigators intended to study and 
that significant sources of variance that do not contri- 
bute to real group differences did not affect the 
groups differentially. 
A negative report by Kaufmann et a1.141 also pres- 
ents the problem of small sample size. Low statistical 
power may not be the major issue in this study, how- 
ever. First, B,, of [3H]QNB binding in fmol of li- 
gand/mg protein was 185 + 80 vs 170 f 66 in the fron- 
tal cortices of suicide and control groups, respective- 
ly. With sufficient sample size, this difference might 
reach statistical significance. Would it to be of practi- 
cal significance, however? Criteria for establishing 
the relevance of an 8% difference would have to be 
established, in consultation with the neurochemist. 
However, with sufficient sample size, the most note- 
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worthy finding to emerge could be a lower B,,, for 
[3H]QNB binding in the hypothalamus of suicide vic- 
tims compared to controls, 122 k 46 vs 187 t 98 fmol 
of ligand/mg protein, respectively. This result pro- 
vides, as the investigators state. a trend in a sample of 
10, but it is opposite to the direction predicted. Such 
a small sample allows bias too easily to obscure or 
create differences between experimental and control 
groups. Perhaps sample size contributed to this unex- 
pected finding. 
A major difficulty in suicide-receptor ligand bind- 
ing studies is the problem of justifiable inference. 
Does documentation of muscarinic receptor up-regu- 
lation in a sample of suicide victims justify the conclu- 
sion that affective illness is associated with muscarin- 
ic receptor up-regulation? Kaufmann and asso- 
ciates”’ acknowledged that they measured musca- 
rinic receptor ligand binding sites not in affective dis- 
order patients but rather in suicide victims. Barra- 
clough” reported that only 53% and 11% in a sample 
of 106 suicide victims met diagnostic criteria for ma- 
jor depression and bipolar disorder, respectively. If 
the average frequency of affective disorder in the 
samples studied by Myerson et al. and Kaufmann et 
al. is 0.53, these samples would include 4.24 and 5.3 
affective disorder subjects. Moreover, the small sam- 
ple sizes of 8 and 10 increase the probability of both 
upward and downward deviation of the mean sample 
frequency of affective illness from the hypothetical 
population mean of 0.53. 
Unidentified sources of variance threaten to di- 
minish the lucidity of any body of data, but they are 
more likely to be limiting when one is working with 
small samples or dealing with certain biological, be- 
havioral, and sociological variables (e.g., suicide, ef- 
fects of genetics on muscarinic receptor binding pa- 
rameters, influences of past and present drug abuse 
and pharmacotherapy on outcome, marital status, 
etc.). One cannot partial out effects of all confound- 
ing variables. but steps can be taken to minimize their 
impact. Some confounding variables can be mea- 
sured and sample size increased in order to reduce 
the chance that the data will be unduly influenced by 
random occurrences. 
Measurement of muscarinic receptor binding pa- 
rameters in larger samples of suicide victims and con- 
trol groups could be valuable. The largest suicide 
study of this type to date involved 22 subjects and 
yielded ‘negative’ results24”. A prospective study 
could be carried out if one had a very large sample of 
affective disorder patients and control subjects, pos- 
sibly non-affectively ill psychiatric patients. Poko- 
ny r’s followed a sample of 4800 patients consecutive- 
ly admitted to the in-patient psychiatric service of a 
Veterans Administration Hospital. During a 5-year 
follow-up period, there were 67 suicides - a rate of 
2.79 deaths per 1000 subjects due to suicide annually, 
which is 12 times the expected frequency. There is 
also a relatively high rate of violent death due to acci- 
dents and homicide in the younger segment of a Vet- 
erans Administration Hospital population, providing 
a logical control group. Thus, a prospective study of 
muscarinic receptor binding parameters in victims of 
suicide with affective and non-affective disorders is 
‘doable’. 
13. TENTATIVE EVIDENCE FOR THE CHOLINERGIC 
HYPOTHESIS: NEUROCHEMICAL EFFECTS OF SLEEP 
DEPRIVATION 
Total and partial REM sleep deprivation produce 
decreases in depressive symptomatology in some en- 
dogenously depressed subjects80*143~‘45~‘s9~197~213~2’4~ 
260,261. There may be an association between depres- 
sive subtype, REM sleep variables, and response to 
sleep deprivation. Subjects responding to sleep de- 
privation are more apt than non-responders to have 
neurovegetative signs and symptoms and rebound in- 
creases in REM pressure following REM depriva- 
tion143-145,159.197.214,224.260,261. Nasrallah and corye1177 
and King et al.‘45 reported that non-suppression to 
dexamethasone challenge predicted positive re- 
sponses to sleep deprivation. 
Bowers et al. l6 studied effects of REM sleep depri- 
vation on acetylcholine levels in the telencephalon 
(cortex, hippocampus and caudate), diencephalon 
(thalamus and hypothalamus), and the brainstem 
posterior to the colliculi and anterior to the obex in 
rats. The animals showed a significant drop in brain 
acetylcholine concentration in the telencephalon af- 
ter 96 h of REM sleep deprivation. These changes do 
not appear to be due to a non-specific effect of stress; 
restraint and activity wheel stress did not produce 
these effects. 
Trusihiya et al.257 studied effects of total, partial, 
and REM sleep deprivation on monoamine and ace- 
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tylcholine content in rat brain. Changes in acetylcho- 
line, serotonin, and norepinephrine content were 
measurable after 10 and 24 h of total sleep depriva- 
tion. Twenty-four hours of partial sleep deprivation 
was associated with an increase in telencephalic ace- 
tylcholine concentration (P < 0.02 two-tailed t-test), 
and a significant decrease in serotonin (P < 0.01, 
two-tailed t-test) and a trend towards reduction in 
norepineph~ne levels (P > 0.05 < P < O.lO), respec- 
tively in the diencephalon. Thirty minutes of sleep 
following 24 h of sleep deprivation increased seroto- 
nin and norepinephrine levels, thus eliminating dif- 
ferences between experiment and control rats. Nine- 
ty-six hours of REM sleep deprivation were asso- 
ciated with a reduction in telencephalic acetylcholine 
concentration of 11.8% (P < 0.05), compared to 8 
control animals. Total sleep deprivation for 24 h 
caused a 22.1% decrease in telencephalic acetylcho- 
line concentration in experimental compared to con- 
trol animals. Ninety-six hours of total REM sleep de- 
privation were also associated with significant de- 
creases in diencephalic and mesencephalic norepi- 
nephrine concentrations. In contrast, serotonin con- 
centrations did not change in any region examined. 
Sagales and Dominoz2* measured steady-state 
whole brain acetylcholine concentration in animals 
deprived of REM sleep for 24, 48 and 96 h and 6 
days. They found no changes. Their methodology, 
however, differed from that employed by Trusihiya 
et a1.257 and Bowers and associate@, in that the lat- 
ter investigators isolated brain regions having poten- 
tially different sensitivities to REM sleep depriva- 
tion. A marked change in acetylcholine concentra- 
tion consequent to the various sleep deprivation ma- 
neuvers could occur at given sites without detectable 
changes in whole brain. 
Total, partial, and REM sleep deprivation might 
also produce important changes in central choliner- 
gic systems not detectable by measuring regional al- 
terations in acetylcholine concentration, In vivo mus- 
carinic receptor binding studies and measurement of 
physiological endpoints promise to be of value in de- 
termining the effects of various forms of sleep depri- 
vation. Binding parameters can be measured in vivo 
in sleep-deprived animals using [3H]scopolamine as 
the receptor ligand. After in vivo administration of 
the radioligand, animals are sacrificed, the brain dis- 
sected, and the regional density of ligand binding 
sites determined using an autoradiographic tech- 
nique. Tracer kinetic modeling conjoined with an au- 
toradiographic technique allows measurement of re- 
ceptor binding site density in ‘infinite’ brain regions 
9 simultaneously - 72. This methodology is more pow- 
erful and less time-consuming than alternatives for 
determining muscarinic receptor binding parameters 
in vivo . 
Systemically administered anticholinesterases and 
cholinomimetics induce hypothermia in rats and 
~~~~5~74~79~146~162.163~172~175~176~192 the magnitude of 
this response before and after sleep deprivation may 
provide a means of monito~ng change in the function 
of a cholinergic mechanism - that is, cholinomimet- 
ic-induced hypothermia can provide an index of the 
sensitivity of cholinergic systems42. This variable may 
also allow study of the effects of different types of 
sleep deprivation on cholinergic mechanisms. Other 
physiological variables are also useful in physiologi- 
cal and receptor binding studies. Moreover, each ani- 
mal can serve as its own control. This design allows 
use of paired parametric statistical models which pro- 
vide greater power than otherwise attainable. Cho- 
linergic activating agents produce cholinergic system 
down-regulation and subsensitivity and modify 
mechanisms regulating the release of acetylcho- 
line20,37,5’.56,165,225,231,251,269,270 It is therefore essen_ 
tial that sufficient time elapses between individual 
cholinergic challenges to avoid carry-over effects, 
i.e. lasting effects produced by the previous pharma- 
cologic challenges. For example, administration of 
an anticholinesterase to ascertain the baseline hy- 
pothermic response to cholinergic overdrive could in- 
terfere with the effects of the sleep deprivation and 
subsequent cholinergic challenges. These design 
problems, however, can generally be overcome. 
The neurophysiology of sleep, sleep pathophysio- 
logy in affective disease, and the biology of sleep de- 
privation may soon be amenable to study using pos- 
itron emission tomographic (PET) strategies. Appro- 
priate muscarinic receptor radioligands are needed. 
In the interim, basic research involving animals is im- 
portant. 
In summary, total, partial, and REM sleep depri- 
vation are effective treatments for some melanchol- 
its. Preliminary studies suggest they alter telenceph- 
alit acetylchohne concentrations. Acetylcholine con- 
centration is a gross measure, and it does not indicate 
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the functional status of cholinergic systems. Mea- 
surement of muscarinic receptor binding parameters 
in vivo and of physiological endpoints should yield 
data more accurately mirroring the effects of sleep 
deprivation procedures on central cholinergic sys- 
tems. 
14. SUMMARY 
Several lines of evidence implicate dysfunction of 
cholinergic systems in the pathophysiology of affec- 
tive disorders. They are best evaluated not only with 
reference to their factual content but also with regard 
for their potential for making future contributions to 
the study of the pathophysiology of affective illness 
and their conceptual significance. For the purpose of 
discussion, however, the evidence for the cholinergic 
hypothesis can be categorized according to the 
strength of factual support they provide. The capaci- 
ty of anticholinesterases and cholinomimetics to pro- 
duce behavioral features of the major affective syn- 
dromes and alter neuroendocrine and polysomnogra- 
phic variables in a direction resembling the endoge- 
nous subtype provide the strongest evidence for a 
cholinergic link in the pathophysiology of affective 
illness. Findings that affective probands and their af- 
fectively ill relatives demonstrate supersensitivity to 
cholinergic challenge relative to control subjects (in- 
cluding non-ill relatives) also provide strong evi- 
dence for the hypothesis. Cholinergic system super- 
sensitivity thus appears to be a heritable trait in sub- 
jects with affective illness. 
Observations that antimuscarinic agents have anti- 
depressant properties are noteworthy but need fur- 
ther evaluation. Cholinergic system supersensitivity 
may be an etiologic factor in affective disease, even 
though anticholinergics are of minimal utility as thy- 
molytics. First, tolerance develops to these agents 
quite quickly. Secondly, cholinergic system super- 
sensitivity is probably just one of many causal fac- 
tors. Antidepressants like amitriptyline and imipra- 
mine are not merely anticholinergic drugs. Sorscher 
and DilsaveZ4’ have emphasized that the neurophar- 
macological effects of drugs are often not revealed by 
reductionistic accounts of their influences on a given 
neurotransmitter system studied in isolation. Interac- 
tion and interregulation of neurotransmitter systems 
is basic to normal neural function. This is certainly 
true of the tricyclics. all of which act on several sys- 
tems simultaneously. Interaction may create a type 
of emergence. Thus, while more rigorously con- 
trolled clinical trials of treatment with antimuscarin- 
its are indicated, the failure of these trials would not 
seriously impugn a cholinergic hypothesis. 
Defects of hedonic capacity in the affective disor- 
ders and roles of cholinergic mechanisms in regula- 
tion of drive reduction behavior in animals suggest 
the importance of basic research in this area. The 
cholinergic and various monoamine hypotheses coal- 
esce to yield accounts of greater explanatory power. 
Previous observations of cholinergic mechanisms in 
the regulation of hedonia are consistent with the hy- 
pothesis that an endogenously arising cholinergic 
overdrive state can produce anhedonia, but ongoing 
research is required before this becomes clinically 
pertinent (i.e., suggests experiments involving hu- 
man subjects testing whether the cholinergic hypoth- 
esis extends to disturbances of hedonic capacity in 
depression). 
Withdrawal of antimuscarinic drugs produces 
many of the characteristic of a depressive syndrome. 
These symptoms are aborted by centrally active 
antimuscarinic agents. These points argue for a type 
of spontaneously occurring cholinergic overdrive in 
certain types of depressive illness. Other drugs of 
abuse block the effects of acetylcholine presynap- 
tically - i.e. directly decrease its release - act on 
monoaminergic systems, or do both simultaneously. 
Presumably, organisms seek what is the best for 
them, and the abuse of substances carries short-term 
benefits. Substance abuse provides a means for the 
self-regulation of mood, affect, and hedonia. Prop- 
erties of abusable substances may be linked to effects 
upon cholinergic networks. The basic pharmacology 
of abusable drugs accords with the possibility that 
disturbances of mood, affect, and hedonic capacity 
involve dysfunction of cholinergic systems. 
Postmortem studies have thus far involved insuffi- 
cient numbers of subjects and have not adequately 
addressed methodological problems. Thus, appro- 
priate tests of the hypothesis that victims of suicide 
have up-regulation of central muscarinic receptors 
remain to be conducted. Future studies will have to 
establish whether subjects really suffered from affec- 
tive disorders. Such studies may have to be done pro- 
spectively. Partial and total sleep deprivation, useful 
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treatments of depression, and inducers of hypomania 
and mania influence cholinergic variables but wheth- 
er their cholinotropic properties relate to their effica- 
cy is not yet known. 
15. FUTURE DIRECTIONS 
15.1. Future directions for studying cholinergic 
mechanisms involved in the pathophysiology of affec- 
tive disorders 
The capacity to produce defects in cholinergic sys- 
tems mimicking those that occur spontaneously in af- 
fective disorder subjects would create many new ex- 
perimental possibilities. Phenomenological, physio- 
logical, biochemical, and receptor binding measures 
are classes of dependent variables that are now useful 
in the study of affective disorders. Abnormalities of 
these variables can result from up-regulation and su- 
persensitivity of choline&c systems and disturb- 
ances of cholinergic-monoaminergic interaction. 
These deviations are safely and inexpensively pro- 
duced by pharmacologic induction of up-regulation 
and supersensitivity of muscarinic cholinergic net- 
works in both man and animals, presenting possibili- 
ties for using antimuscarinic agents in affective disor- 
der investigations. 
Hypotheses formulated by considering clinical 
data can be tested by applying pharmacological per- 
turbation techniques in animals. A pathophysiologic 
role for supersensitivity of cholinergic systems in af- 
fective disease can be verified in humans by compar- 
ing cholinomimetic-induced changes in variables in 
affectively ill patients and in normal subjects before, 
during, and after chronic muscarinic receptor block- 
ade. Dependent variables partially regulated by cho- 
linergic systems include mood and affect, psychomo- 
tor function87-8g, hedonic capacity (behavioral varia- 
bles), body temperature, pupillary dynamic8’3 
47*228,22g, REM latency and density, percent of REM 
during the first half of the nocturnal recording, sleep 
efficiency, DST status, absolute post-dexametha- 
sone cortisol from a /3-endorphin, ACTH concentra- 
tions, the distribution of regional EEG activity or 
power-spectral analysis253 (physiological variables), 
and rates of cyclic GMP generation57,133T134,240 
or phospholipid turnover (biochemical vari- 
ables) . 52,63-65 
15.2. Future directions: Use of normal subjects in 
modeling cholinergic abnormalities of depressive dis- 
orders 
A conceptual framework for use of pharmacologic 
perturbation or modeling strategies has been pre- 
sented elsewhere47. Effects of antimuscarinics can be 
measured in normal subjects using a design allowing 
them to serve as their own controls. These subjects 
could be compared to affective disorder subjects at 
any point of interest. Adverse effects of muscarinic 
receptor blockade should not be so severe as to pro- 
hibit such studies; doses of centrally active anticho- 
linergic agents sufficient to produce the desired phys- 
iological and psychic effects have been administered 
to humans without ontoward effects1.‘4,‘8*24,33.59. 
86,123,126.131,140,190,199,215,238.252.253,256.267,268 
Bringing together the interests and expertise of ba- 
sic and clinical scientists by using these drugs to ma- 
nipulate neurotransmitter systems on several levels, 
molecular to organismic, may prove particularly 
fruitful. For instance, withdrawal of tricyclics was 
found in the clinic to produce evidence of mesolim- 
bit, mesocortical and nigrostriatal cholinergic over- 
drive and LHPA dysregulation. In subsequent labo- 
ratory studies, we observed treatment with amitrip- 
tyline (10 or 15 or 20 mg/kg i.p. twice daily) for 7 or 
more days markedly shifted the dose-response curve 
for induction of hypothermia by oxotremorine in 
Sprague-Dawley rats. That is, amitriptyline, super- 
sensitized a cholinergic system as evidenced by 
change in the magnitude of the hypothermia pro- 
duced by challenge with oxotremorine, 0.10 and 0.25 
or 1.0 mg/kg, before and after treatment (P < 0.05, 
ANOVA with repeated measures)41. The strategy of 
proceeding from man (clinical observations) to the 
intact animal (physiology) was quite useful. 
15.3. Future directions: Defining the limits and scope 
of cholinergic abnormalities in the pathophysiology of 
affective disorders 
There is strong support for the hypothesis that cho- 
linergic mechanisms are operative in the pathophy- 
siology of depressive disorders. Determining the lim- 
it and scope of their contribution to the phenomena 
of depressive disorders, however, is of critical impor- 
ante. It is all too easy to fall into the trap of consider- 
ing cholinergic activity in isolation. If the nature of 
cholinergic systems is to be properly understood, in- 
teraction with other neurotransmitter systems (e.g., 
adrenergic, dopaminergic, serotonergic, GABAer- 
gic. peptidergic) must be carefully considered and 
clarified. The question we should be asking is. “What 
aspects of the phenomenological, neuroendocrinolo- 
gical, polysomnographic, diurnal, and autonomic ab- 
normalities of affective disorders are related to the 
pathology of muscarinic cholinergic systems, and 
what aspects are due to abnormal interaction of cho- 
linergic and other systems?” 
We must first adopt criteria by which to determine 
whether a cholinergic component is involved at all. 
To begin with, we must establish a clear relationship 
between dependent variables (mood, affect, neuro- 
endocrine status, pupillometric measures, etc.) and 
naturally or pharmacology-induced cholinergic over- 
drive. Secondly, we must identify cholinergic path- 
ways or the anatomic substrata of deranged choliner- 
gic mechanisms involved in producing those relation- 
ships between dependent variables and cholinergic 
overdrive. Studies of sleep disturbance are exem- 
plary in this respect. Hobson and McCar- 
ley 101-*os~169~‘70 (cf. Section 5) have posited a dynamic 
interaction between a cholinergic network confined 
to the J?TG (a pontine structure) and an adrenergic 
network, the locus coeruleus. Activation of the FTG 
tends to produce increased REM density and REM 
latency. features of melancholia. Thus, the challenge 
of verifying the relationship between sleep variables 
and cholinergic overdrive and of identifying the spe- 
cific cholinergic pathways involved has helped to ex- 
tend the frontiers of our knowledge. 
15.4. Future directions: Defining the loci of choliner- 
gic abnormalities involved in the pathophysiology of 
uffective d~orders 
Future study into the etiology of affective disor- 
ders may profit from a broadened conceptualization 
of the nature of the underlying cholinergic defect. 
Current evidence pointing to supersensitivity of cho- 
hnergic systems does not indicate the site of dysregu- 
lation. Typically, the locus of abnormality is implied 
to be the postsynaptic muscarinic receptor. Choliner- 
gic phenomena observed in affective disorder pa- 
tients, however, could also result from abnormal pre- 
synaptic mechanisms, membrane pathophysiology or 
derangement of intra-cytosolic mechanisms intended 
to amplify the effectiveness of receptor-agonist cou- 
pling, or aberrant cholinergic-monoaminergic inter- 
action. For example. presynaptic mechanisms regu- 
late the release of acetylcholine. Defects of the pre- 
synaptic autoreceptor could promote excessive re- 
lease of acetylcholine, leading to an endogenously 
arising cholinergic overdrive state. The possibility of 
pathophysiology at the level of the receptor, in the 
regulation of receptor density, in presynaptic control 
of acetylcholine release, in membrane dynamics, or 
in cascade mechanisms was recently addressed4’. 
This type of dissection can help to promote clarity of 
thought in this area of research and to suggest alter- 
native approaches to the topic of cholinergic system 
supersensitivity in the pathophysiology of affective 
illness. 
15.5. Further directions: Beyond the cholinergic hy- 
pothesis 
Cholinergic pathology is not likely to explain ‘all 
the variance’. There are features of the depressed 
state or of the longitudinal course of affective disor- 
ders that may be best understood in terms of the in- 
teraction between cholinergic and monoaminergic 
systems or of other factors. 
Efforts to deepen our understanding of any natural 
phenomenon demand hypotheses, and hypotheses 
are amenable to verification, at least in principle. 
Verification or validation can mean ‘to establish as 
true or false’, using accepted methodology, applica- 
tion of the canons of data analysis, and standards of 
interpretation prevailing in a field. In actuality, vali- 
dation may mean that given h~o~heses come to be 
recognized as being ‘reasonable’ or ‘worthy’ of ac- 
ceptance. The value of hypotheses lies in their capac- 
ity to stimulate fruitful intellectual activity - i.e., to 
increase understanding of phenomena, generate im- 
portant questions for scrutiny, and promote the ame- 
lioration of human suffering. 
The pathophysiology of the affective disorders has 
been studied from many perspectives. Within biolog- 
ical circles, the two approaches that have enjoyed the 
greatest influence are the various ‘monoaminergic’ 
hypotheses21~22,32.223,258 and the cholinergic1’4 hy- 
pothesis. Both have served their purposes well; both 
have tremendous heuristic value. Nevertheless, if 
one insists that a hypothesis is verified or validated 
only if it provides a sufficient and adequate explana- 
tion for a phenomenon, then both are ‘false’. Howev- 
er, application of such a rigid standard of truth to hy- 
potheses tends to lead to their devaluation. It is diffi- 
cult to integrate all of the available knowledge perti- 
nent to the topic of this article but integration alone 
does justice to those who articulated and studied the 
various hypotheses we are discussing. Integration of 
knowledge regarding the inter- and intraregulation 
of cholinergic and monoaminergic (dopaminergic, 
adrenergic, serotonergic) systems provides new and 
powerful means of viewing and understanding old 
phenomena. It can create ‘realities’, by making us 
aware of possibilities that we would not otherwise ap- 
preciate . 15* Integration can raise questions which 
would not ordinarily be asked and it can thus lead to 
answers which would not have otherwise been 
sought. Hence, it proceeds from an existing body of 
knowledge to new knowledge. 
In my judgment, affective disorders research is in 
need of not only the integration of seemingly dispa- 
rate perspectives (e.g., cholinergic, monoaminer- 
gic), but the development of comprehensive models 
fostering basic research pari passu with clinical stud- 
ies. Such models would focus on the study of relevant 
phenomena based on the critical examination of mul- 
tiple phenomenological, physiological, biochemical, 
and brain imaging variables in normal and ill human 
subjects and laboratory animals. Our task is one of 
synthesis rather than multiplication of hypotheses, of 
collaboration rather than fragmentation. The impor- 
tance of the body of research described in this review 
lies not only in the contribution it has made toward 
promoting knowledge and ameliorating human pain, 
but also in the solid basis it provides for building the 
conceptually broader models needed for the future. 
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